<?xml version="1.0" encoding="UTF-8"?>
<CustomObjectTranslation xmlns="http://soap.sforce.com/2006/04/metadata">
    <caseValues>
        <plural>false</plural>
        <value>Interaction Discussion</value>
    </caseValues>
    <caseValues>
        <plural>true</plural>
        <value>Interaction Discussions</value>
    </caseValues>
    <fields>
        <label><!-- Account_Source_Country_BMS_CORE --></label>
        <name>Account_Source_Country_BMS_CORE__c</name>
    </fields>
    <fields>
        <label><!-- Account Tactic --></label>
        <name>Account_Tactic_vod__c</name>
        <relationshipLabel><!-- Interaction Discussions (Account Tactic) --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Account --></label>
        <name>Account_vod__c</name>
        <relationshipLabel>Call Discussions(Accounts)</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Activity ID --></label>
        <name>Activity_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Activity --></label>
        <name>Activity__c</name>
        <picklistValues>
            <masterLabel>Contracts Discussion</masterLabel>
            <translation><!-- Contracts Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dinner meeting</masterLabel>
            <translation><!-- Dinner meeting --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Email exchange</masterLabel>
            <translation><!-- Email exchange --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lunch meeting</masterLabel>
            <translation><!-- Lunch meeting --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Meeting</masterLabel>
            <translation><!-- Meeting --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Presentation</masterLabel>
            <translation><!-- Presentation --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Answer --></label>
        <name>Answer_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Attendee Type --></label>
        <name>Attendee_Type_vod__c</name>
        <picklistValues>
            <masterLabel>Contact_vod</masterLabel>
            <translation>Contact</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Event_vod</masterLabel>
            <translation>Event</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Group_Account_vod</masterLabel>
            <translation>Group Account</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Person_Account_vod</masterLabel>
            <translation>Person Account</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>User_vod</masterLabel>
            <translation>User</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Barrier Reason --></label>
        <name>Barrier_Reason_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Concern on  safety of high dosage of Glucophage</masterLabel>
            <translation><!-- Concern on  safety of high dosage of Glucophage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Concern on  safety of long term usage of Glucophage</masterLabel>
            <translation><!-- Concern on  safety of long term usage of Glucophage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_1_1</masterLabel>
            <translation>LWMH适应症广泛包括髋部骨折手术</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_1_2</masterLabel>
            <translation>LWMH长期使用经验，安全</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_1_3</masterLabel>
            <translation>各国指南优先推荐LWMH</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_2_1</masterLabel>
            <translation>拜瑞妥第一个口服NOAC，中国骨科指南推荐</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_2_2</masterLabel>
            <translation>拜瑞妥QD，依从性好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_3_1</masterLabel>
            <translation>艾乐妥BID，患者依从性差</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_3_2</masterLabel>
            <translation>目前没有证据表明艾乐妥优于拜瑞妥</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_3_3</masterLabel>
            <translation>艾乐妥价格贵，未在医保</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_BR_1_4_1</masterLabel>
            <translation>达成目标：首选艾乐妥预防VTE，THR患者推荐为35天(7盒)，TKR患者为14天(3盒)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_BR_Achieved</masterLabel>
            <translation><!-- Glu_BR_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_1_1</masterLabel>
            <translation>临床上有很多降压药可选，蒙诺最近几年没怎么听说过。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_2_1</masterLabel>
            <translation>由于中国患者ACEI咳嗽更多的问题, 导致较多的临床医生为图方便,而选用了ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_2_2</masterLabel>
            <translation>ARB也有很多较少心肌重构、改善中间指标的研究</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_3_1</masterLabel>
            <translation>蒙诺的心血管保护证据不如雅施达充足</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_1_3_2</masterLabel>
            <translation>洛汀新的组织亲和力更高，保护更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_2_2_2</masterLabel>
            <translation>ARB在抗动脉粥样硬化、改善心肌重构等方面具有丰富证据</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_2_2_3</masterLabel>
            <translation>ACEI降压幅度弱于ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_2_3_3</masterLabel>
            <translation>洛汀新、雅施达有新研究</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_3_2_2</masterLabel>
            <translation>ARB也是指南推荐的心衰治疗药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_3_2_3</masterLabel>
            <translation>ARB特别是缬沙坦和氯沙坦有心衰治疗的临床研究数据</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_4_3_1</masterLabel>
            <translation>雅施达半衰期24小时，且T/P比值100%</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_BR_Achieved</masterLabel>
            <translation>达成目标：Protect you today, for the future outcome</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>More earlier combination therapy instead of titrate to Metformin optimal dosage</masterLabel>
            <translation><!-- More earlier combination therapy instead of titrate to Metformin optimal dosage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_1_1</masterLabel>
            <translation>SU降糖效果较强</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_1_2</masterLabel>
            <translation>对于双胍单药失效的患者,首选加用SU,因为SU与双胍作用机制不同，联合治疗降糖更佳,使用经验丰富</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_2_1</masterLabel>
            <translation>安立泽降糖效果弱</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_2_2</masterLabel>
            <translation>安立泽自费药，价格偏贵</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_3_1</masterLabel>
            <translation>指南推荐DPP－4抑制剂作为二线用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_1_3_2</masterLabel>
            <translation>安立泽价格贵</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_BR_2_1_2</masterLabel>
            <translation>SU价格便宜</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_1</masterLabel>
            <translation>认为顺铂是NCCN指南的一类推荐，比卡铂更有效，临床数据更多</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_2</masterLabel>
            <translation>&quot;轻视了顺铂肾毒性危险,认为肾功能正常的患者不需大量水化&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_3</masterLabel>
            <translation>认为顺铂的呕吐反应可以控制</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_4</masterLabel>
            <translation>认为顺铂的耳毒性不明显</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_5</masterLabel>
            <translation>担心卡铂引起的血小板减少副反应</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_1_6</masterLabel>
            <translation>AUC计算卡铂剂量的方法应用起来不方便</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_1_2_1</masterLabel>
            <translation>伯尔定（卡铂）:达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_1_1</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心伯尔定的疗效劣于顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_1_2</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心伯尔定的安全性低于顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_2_1</masterLabel>
            <translation>&quot;在铂敏感型复发卵巢癌中,担心伯尔定的疗效没有超过顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_BR_2_2_2</masterLabel>
            <translation>&quot;在铂敏感型复发卵巢癌中,担心伯尔定的安全性低于顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prescriber believe PPG control is the important attributes in Type 2 DM</masterLabel>
            <translation><!-- Prescriber believe PPG control is the important attributes in Type 2 DM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prescriber misunderstanding Glucophage side effect</masterLabel>
            <translation><!-- Prescriber misunderstanding Glucophage side effect --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_1</masterLabel>
            <translation>不相信在蒽环类方案中增加泰素?可以提高疗效</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_2</masterLabel>
            <translation>担心蒽环类联合泰素?可能增加毒副反应</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_3</masterLabel>
            <translation>不认为泰素的疗效比仿制品更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_1_4</masterLabel>
            <translation>担心使用泰素引起的过敏反应</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_2_1</masterLabel>
            <translation>不认为没有使用足周期的泰素?方案会对疗效有影响</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_1_3_1</masterLabel>
            <translation>泰素:达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_1</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心Taxol方案疗效和安全性不优于多西他赛的方案&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_2</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心Taxol方案疗效不优于力朴素/白蛋白紫杉醇的方案&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_4</masterLabel>
            <translation>Anzatax是原研紫杉醇</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_1_5</masterLabel>
            <translation>&quot;在晚期卵巢癌中,接受力朴素无需预处理观念&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_2_1</masterLabel>
            <translation>&quot;在铂敏感型复发卵巢癌中,担心Taxol方案疗效和安全性不优于多西他赛的方案&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_2_2</masterLabel>
            <translation>&quot;在铂敏感型复发卵巢癌中,担心Taxol方案疗效不优于力朴素/白蛋白紫杉醇的方案&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_2_5</masterLabel>
            <translation>&quot;在铂敏感型复发卵巢癌中,接受力朴素无需预处理的观念&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_BR_2_3_1</masterLabel>
            <translation>担心是否耐受6-8个周期的泰素化疗方案</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Call Mobile ID --></label>
        <name>Call2_Mobile_ID_vod__c</name>
    </fields>
    <fields>
        <label><!-- Call --></label>
        <name>Call2_vod__c</name>
        <relationshipLabel>Call Discussions</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Date --></label>
        <name>Call_Date_vod__c</name>
    </fields>
    <fields>
        <label><!-- Clinical Trial --></label>
        <name>Clinical_Trial_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>ACTION</masterLabel>
            <translation><!-- ACTION --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AEGEAN</masterLabel>
            <translation><!-- AEGEAN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AEGEAN (Adherence)</masterLabel>
            <translation><!-- AEGEAN (Adherence) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI424-402 study: HARNESS ATV+RAL</masterLabel>
            <translation><!-- AI424-402 study: HARNESS ATV+RAL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI424-494 study: ATV/r + 3TC</masterLabel>
            <translation><!-- AI424-494 study: ATV/r + 3TC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI438-011: Safety, efficacy, dose finding BMS-663068 in treatment exp.</masterLabel>
            <translation><!-- AI438-011: Safety, efficacy, dose finding BMS-663068 in treatment exp. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AI467-003: Safety, efficacy, dose finding BMS-986001 in treatment naïve</masterLabel>
            <translation><!-- AI467-003: Safety, efficacy, dose finding BMS-986001 in treatment naïve --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ALLURE</masterLabel>
            <translation><!-- ALLURE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AMPLIFY</masterLabel>
            <translation><!-- AMPLIFY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ANNEXA-A (Portola Ph 3)</masterLabel>
            <translation><!-- ANNEXA-A (Portola Ph 3) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APPIPRA</masterLabel>
            <translation><!-- APPIPRA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARCADIA</masterLabel>
            <translation><!-- ARCADIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARTESiA (Subclinical AF)</masterLabel>
            <translation><!-- ARTESiA (Subclinical AF) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ASCORE</masterLabel>
            <translation><!-- ASCORE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ASSET</masterLabel>
            <translation><!-- ASSET --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ASTREA</masterLabel>
            <translation><!-- ASTREA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATLANTIS (TAVI)</masterLabel>
            <translation><!-- ATLANTIS (TAVI) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AUGUSTUS (Safety)</masterLabel>
            <translation><!-- AUGUSTUS (Safety) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVERT-2</masterLabel>
            <translation><!-- AVERT-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AXAFA (Ablation)</masterLabel>
            <translation><!-- AXAFA (Ablation) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ 19 - safety and efficacy in CV risk pts (ST + LT)</masterLabel>
            <translation><!-- AZ 19 - safety and efficacy in CV risk pts (ST + LT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ04/BMS 022 - add on to met failures</masterLabel>
            <translation><!-- AZ04/BMS 022 - add on to met failures --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ06/BMS 33 LTE - add on to insulin</masterLabel>
            <translation><!-- AZ06/BMS 33 LTE - add on to insulin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ10/BMS 61 - add on to DPP-IV (ST + LT)</masterLabel>
            <translation><!-- AZ10/BMS 61 - add on to DPP-IV (ST + LT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AZ18/BMS 67 - safety and efficacy in CV risk pts (ST+LT)</masterLabel>
            <translation><!-- AZ18/BMS 67 - safety and efficacy in CV risk pts (ST+LT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adjuvant 029</masterLabel>
            <translation><!-- Adjuvant 029 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS 029 - Moderate RI</masterLabel>
            <translation><!-- BMS 029 - Moderate RI --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS 073 - Blood pressure</masterLabel>
            <translation><!-- BMS 073 - Blood pressure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS 077 - Follow on Blood pressure study</masterLabel>
            <translation><!-- BMS 077 - Follow on Blood pressure study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 184-437 Ipi 3 vs. 10 in CRPC</masterLabel>
            <translation><!-- CA 184-437 Ipi 3 vs. 10 in CRPC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 186-011 Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&apos;s Lymphoma</masterLabel>
            <translation><!-- CA 186-011 Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin&apos;s Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 186-017 Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL</masterLabel>
            <translation><!-- CA 186-017 Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 204-004 ELOQUENT-2</masterLabel>
            <translation><!-- CA 204-004 ELOQUENT-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 204-006 ELOQUENT-1</masterLabel>
            <translation><!-- CA 204-006 ELOQUENT-1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-205 Nivo in cl. Hodgkin Lymphoma</masterLabel>
            <translation><!-- CA 209-205 Nivo in cl. Hodgkin Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-214 Nivo in RCC</masterLabel>
            <translation><!-- CA 209-214 Nivo in RCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-227 NSCLC</masterLabel>
            <translation><!-- CA 209-227 NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-238 Nivo vs. Ipi adjuvant melanoma</masterLabel>
            <translation><!-- CA 209-238 Nivo vs. Ipi adjuvant melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-275 Nivo in urothelial</masterLabel>
            <translation><!-- CA 209-275 Nivo in urothelial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA 209-331 SCLC</masterLabel>
            <translation><!-- CA 209-331 SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-226 Pediatric</masterLabel>
            <translation><!-- CA180-226 Pediatric --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-330 SIMPLICITY</masterLabel>
            <translation><!-- CA180-330 SIMPLICITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-399 DASCERN</masterLabel>
            <translation><!-- CA180-399 DASCERN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA180-406 DASFREE</masterLabel>
            <translation><!-- CA180-406 DASFREE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA184-143 IMAGE</masterLabel>
            <translation><!-- CA184-143 IMAGE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA186-011 B-NH Lymphoma</masterLabel>
            <translation><!-- CA186-011 B-NH Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA204-008 PREAMBLE</masterLabel>
            <translation><!-- CA204-008 PREAMBLE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA204-125 ELOQUENT-3</masterLabel>
            <translation><!-- CA204-125 ELOQUENT-3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-026 1st Line Lung</masterLabel>
            <translation><!-- CA209-026 1st Line Lung --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-032 Solid Tumors</masterLabel>
            <translation><!-- CA209-032 Solid Tumors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-139 DLBC Lymphoma</masterLabel>
            <translation><!-- CA209-139 DLBC Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-140 Follicular Lymph</masterLabel>
            <translation><!-- CA209-140 Follicular Lymph --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-141 Head &amp; Neck</masterLabel>
            <translation><!-- CA209-141 Head &amp; Neck --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-142</masterLabel>
            <translation><!-- CA209-142 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-142 CRC</masterLabel>
            <translation><!-- CA209-142 CRC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-143 GBM</masterLabel>
            <translation><!-- CA209-143 GBM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-171 Lung</masterLabel>
            <translation><!-- CA209-171 Lung --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-172 Melanoma</masterLabel>
            <translation><!-- CA209-172 Melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-205 cHL-ASCT</masterLabel>
            <translation><!-- CA209-205 cHL-ASCT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-214 RCC</masterLabel>
            <translation><!-- CA209-214 RCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-227 NSCLC</masterLabel>
            <translation><!-- CA209-227 NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-234 RWD</masterLabel>
            <translation><!-- CA209-234 RWD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-238 Adj Melanoma</masterLabel>
            <translation><!-- CA209-238 Adj Melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-274 Bladder / Urothelial</masterLabel>
            <translation><!-- CA209-274 Bladder / Urothelial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-275 Urethral</masterLabel>
            <translation><!-- CA209-275 Urethral --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-331 SCLC</masterLabel>
            <translation><!-- CA209-331 SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-357 OPTIMIzE</masterLabel>
            <translation><!-- CA209-357 OPTIMIzE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-370 SUSTAIN</masterLabel>
            <translation><!-- CA209-370 SUSTAIN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-384 Dose freq. opt</masterLabel>
            <translation><!-- CA209-384 Dose freq. opt --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-401</masterLabel>
            <translation><!-- CA209-401 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-417 Lung</masterLabel>
            <translation><!-- CA209-417 Lung --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-436 NHL</masterLabel>
            <translation><!-- CA209-436 NHL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-451 SCLC</masterLabel>
            <translation><!-- CA209-451 SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-459 HCC</masterLabel>
            <translation><!-- CA209-459 HCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-511 Melanoma Dose Combi</masterLabel>
            <translation><!-- CA209-511 Melanoma Dose Combi --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-568 NSCLC</masterLabel>
            <translation><!-- CA209-568 NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-577 Oesophageal</masterLabel>
            <translation><!-- CA209-577 Oesophageal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CA209-744 cHL in children, adolescents &amp; young adults</masterLabel>
            <translation><!-- CA209-744 cHL in children, adolescents &amp; young adults --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN138-502</masterLabel>
            <translation><!-- CN138-502 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CRC-142</masterLabel>
            <translation><!-- CRC-142 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CV 185-316 Safety of Apixaban vs. VKA+Aspirin vs. Aspirin Placebo in Patients with AF and ACS or Percutaneous Coronary Intervention</masterLabel>
            <translation><!-- CV 185-316 Safety of Apixaban vs. VKA+Aspirin vs. Aspirin Placebo in Patients with AF and ACS or Percutaneous Coronary Intervention --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clazakizumab trials</masterLabel>
            <translation><!-- Clazakizumab trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASCERN CA180-399</masterLabel>
            <translation><!-- DASCERN CA180-399 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASFREE CA180-406</masterLabel>
            <translation><!-- DASFREE CA180-406 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASPERSE CA180-400</masterLabel>
            <translation><!-- DASPERSE CA180-400 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DasaRealise</masterLabel>
            <translation><!-- DasaRealise --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EMANATE (Cardioversion)</masterLabel>
            <translation><!-- EMANATE (Cardioversion) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EVIDENS</masterLabel>
            <translation><!-- EVIDENS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GBM-143</masterLabel>
            <translation><!-- GBM-143 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GENERATION</masterLabel>
            <translation><!-- GENERATION --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Head&amp;Neck-141</masterLabel>
            <translation><!-- Head&amp;Neck-141 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ICoSRA</masterLabel>
            <translation><!-- ICoSRA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-179</masterLabel>
            <translation><!-- IM101-179 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-240 JIA</masterLabel>
            <translation><!-- IM101-240 JIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-301 SC in JIA</masterLabel>
            <translation><!-- IM101-301 SC in JIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM101-550 AVERT-2</masterLabel>
            <translation><!-- IM101-550 AVERT-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM127-028 Lupus Erythematosus</masterLabel>
            <translation><!-- IM127-028 Lupus Erythematosus --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IM140-103 ITP</masterLabel>
            <translation><!-- IM140-103 ITP --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMAGE</masterLabel>
            <translation><!-- IMAGE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Investigator Sponsored Research</masterLabel>
            <translation><!-- Investigator Sponsored Research --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung 104</masterLabel>
            <translation><!-- Lung 104 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung 156</masterLabel>
            <translation><!-- Lung 156 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung-026</masterLabel>
            <translation><!-- Lung-026 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lung-171</masterLabel>
            <translation><!-- Lung-171 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lymphoma-139</masterLabel>
            <translation><!-- Lymphoma-139 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lymphoma-140</masterLabel>
            <translation><!-- Lymphoma-140 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>N-SqNSCLC-057</masterLabel>
            <translation><!-- N-SqNSCLC-057 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other trials</masterLabel>
            <translation><!-- Other trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PREAMBLE</masterLabel>
            <translation><!-- PREAMBLE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pediatric CML trial 226</masterLabel>
            <translation><!-- Pediatric CML trial 226 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prostate 043</masterLabel>
            <translation><!-- Prostate 043 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prostate 095</masterLabel>
            <translation><!-- Prostate 095 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prostate 227</masterLabel>
            <translation><!-- Prostate 227 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RA-ILD</masterLabel>
            <translation><!-- RA-ILD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RCC-025</masterLabel>
            <translation><!-- RCC-025 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RENAL-AF (Hemodialysis)</masterLabel>
            <translation><!-- RENAL-AF (Hemodialysis) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SAVOR</masterLabel>
            <translation><!-- SAVOR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SIMPLICITY</masterLabel>
            <translation><!-- SIMPLICITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SqNSCLC-017</masterLabel>
            <translation><!-- SqNSCLC-017 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>T1DM</masterLabel>
            <translation><!-- T1DM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VTE Treatment in Cancer</masterLabel>
            <translation><!-- VTE Treatment in Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>mMel-067</masterLabel>
            <translation><!-- mMel-067 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>mMel-172</masterLabel>
            <translation><!-- mMel-172 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Clinical Trial Protocol --></label>
        <name>Clinical_Trial_Protocol_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Clinical Trial Site --></label>
        <name>Clinical_Trial_Site_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Comments --></label>
        <name>Comments__c</name>
    </fields>
    <fields>
        <label><!-- Contact --></label>
        <name>Contact_vod__c</name>
        <relationshipLabel>Call Discussions(Contacts)</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Country --></label>
        <name>Country_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Country ID --></label>
        <name>Country_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Deck ID --></label>
        <name>Deck_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Detail Group --></label>
        <name>Detail_Group_vod__c</name>
        <relationshipLabel><!-- Call Discussions (Detail Group) --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Discussion Topics --></label>
        <name>Discussion_Topics__c</name>
        <picklistValues>
            <masterLabel>Discussion Topic 1</masterLabel>
            <translation><!-- Discussion Topic 1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 2</masterLabel>
            <translation><!-- Discussion Topic 2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 3</masterLabel>
            <translation><!-- Discussion Topic 3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 4</masterLabel>
            <translation><!-- Discussion Topic 4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion Topic 5</masterLabel>
            <translation><!-- Discussion Topic 5 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Disease State Deck</label>
        <name>Disease_State_Proactive_Deck_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Driver Reason --></label>
        <name>Driver_Reason_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Baraclude_Achieved</masterLabel>
            <translation><!-- Baraclude_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cost effective</masterLabel>
            <translation><!-- Cost effective --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DM long term goal is to reduce mortality due to macro-vascular complication</masterLabel>
            <translation><!-- DM long term goal is to reduce mortality due to macro-vascular complication --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_1_1</masterLabel>
            <translation>ADVANCE研究证实，与LWMH相比，艾乐妥显著降低VTE发生，且不增加出血风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_1_2</masterLabel>
            <translation>艾乐妥优化口服给药，一天两次，提供更佳的疗效与安全性平衡</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_1</masterLabel>
            <translation>口服给药，方便患者住院和出院连续治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_2</masterLabel>
            <translation>艾乐妥12~24h用药更符合临床实践，相比拜瑞妥6~8h,有更多的时间使创口充分止血，可在术后恶心和呕吐发生率降低后使用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_3</masterLabel>
            <translation>荟萃研究显示，相比依诺肝素，艾乐妥的临床相关出血风险显著降低，而利伐沙班的临床相关出血风险显著增高</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_2_4</masterLabel>
            <translation>拜瑞妥肾脏清楚率高达66%，而艾乐妥肾脏负担小，更适合老年人使用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_3_1</masterLabel>
            <translation>艾乐妥THR患者推荐为35天(7盒)，TKR患者为14天(3盒)，符合ACCP9 指南“VTE预防时限至少应用10-14天，应延长至35天</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_DR_1_4_1</masterLabel>
            <translation>达成目标：首选艾乐妥预防VTE，THR患者推荐为35天(7盒)，TKR患者为14天(3盒)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_DR_Achieved</masterLabel>
            <translation>达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage unique CV protection eviidence</masterLabel>
            <translation><!-- Glucophage unique CV protection eviidence --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guideline recommend Metformin as the best choice of initial therapy</masterLabel>
            <translation><!-- Guideline recommend Metformin as the best choice of initial therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_1_1</masterLabel>
            <translation>作为发明第一个ACEI的公司，2012BMS单独成立CV BU，全力发展心血管业务</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_1_2</masterLabel>
            <translation>ACEI循证医学证据丰富且有硬终点，不能耐受咳嗽的患者毕竟是少数</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_1_3</masterLabel>
            <translation>ACEI在指南中的地位确实比ARB高</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_3_1</masterLabel>
            <translation>蒙诺FAMIS研究及后续随访充分证实其在急性心梗的疗效</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_1_3_2</masterLabel>
            <translation>组织亲和力是一个体外指标，蒙诺和洛汀新一样是高组织亲和力的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_2_2_3</masterLabel>
            <translation>对于心绞痛患者来说，减少心梗、心衰及心源性死亡的风险来自降压和神经内分泌调节，ACEI已被证实在降压外有额外的降低9%冠心病风险的能力</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_2_3_1</masterLabel>
            <translation>蒙诺可通过改善PAI-1及抗动脉粥样硬化，改善心绞痛患者预后最核心的两项指标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_2_3_2</masterLabel>
            <translation>蒙诺是第三代ACEI，具有进化优势</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_3_2_1</masterLabel>
            <translation>新指南强化了ACEI是心衰治疗基石的地位</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_3_2_3</masterLabel>
            <translation>氯沙坦和缬沙坦在HF取得的研究结果未能超与开博通，且常为复合终点有意义，硬终点都没能达到预设目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_3_3_1</masterLabel>
            <translation>美国退伍军人研究和美国FDA培哚普利和贝那普利的适应症的差别充分说明蒙诺在心衰治疗方面有显著优势</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_4_2_1</masterLabel>
            <translation>2012最新的荟萃分析充分肯定了ACEI较ARB在减少高血压患者全因死亡方面的优势</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_4_2_2</masterLabel>
            <translation>ACEI降压能力和使用剂量相关，既往研究显示ACEI也能很好降压</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_4_3_1</masterLabel>
            <translation>欧洲共识及研究证实蒙诺是T/P比值最高的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_DR_Achieved</masterLabel>
            <translation>达成目标：Protect you today, for the future outcome</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Not Receive</masterLabel>
            <translation><!-- Not Receive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_1</masterLabel>
            <translation>应用SU发生低血糖的患者应换用其他低血糖发生率低的药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_2</masterLabel>
            <translation>安立泽低血糖风险极小，使用方便，无需调整剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_3</masterLabel>
            <translation>安立泽联合双胍，降糖效果与SU联合双胍相似</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_1_4</masterLabel>
            <translation>安立泽是新型OAD，需要建立临床经验，有尝试意愿</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_1</masterLabel>
            <translation>SU低血糖风险高，使用不方便</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_2</masterLabel>
            <translation>AGI胃肠道副作用发生率较高，使用不方便</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_3</masterLabel>
            <translation>安立泽低血糖风险小，使用方便，无需调整剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_2_4</masterLabel>
            <translation>安立泽胃肠道副作用发生率小</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_3_1</masterLabel>
            <translation>安立泽可以控制FPG、PPG和HbA1c。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_1_3_3</masterLabel>
            <translation>安立泽对心血管和B细胞有潜在保护作用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_2_2_5</masterLabel>
            <translation>安立泽降糖效果与SU相似</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_2_3_2</masterLabel>
            <translation>新病人以PPG升高为主，安立泽在全面控糖的同时控制PPG效果更好，适用于新病人</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_DR_2_3_4</masterLabel>
            <translation>安立泽对心血管和B细胞有潜在的保护作用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_1</masterLabel>
            <translation>NCCN指南推荐卡铂方案是SCLC的标准一线化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_2</masterLabel>
            <translation>与顺铂方案相比，伯尔定?(卡铂)方案可获得相似的生存获益</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_3</masterLabel>
            <translation>与顺铂相比， 伯尔定?(卡铂) 的药代动力学更有利，排泄更迅速</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_4</masterLabel>
            <translation>&quot;与顺铂相比，伯尔定?(卡铂)的肾毒性发生率更低,(高血压和糖尿病患者GFR下降)&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_5</masterLabel>
            <translation>与顺铂相比，伯尔定?(卡铂)无需大容量水化及利尿，且输注时间短</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_6</masterLabel>
            <translation>与顺铂相比，伯尔定?(卡铂)的胃肠毒性和耳毒性发生更少</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_7</masterLabel>
            <translation>&quot;血小板减少为卡铂的剂量限制性毒性,可逆&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_8</masterLabel>
            <translation>伯尔定?(卡铂)利用AUC通过 Calvert公式计算个体化给药剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_1_9</masterLabel>
            <translation>伯尔定?为原研进口卡铂注射液</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_1_2_1</masterLabel>
            <translation>伯尔定?(卡铂) :达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_1_1</masterLabel>
            <translation>国内外指南推荐：卡铂作为晚期卵巢癌首选化疗药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_1_2</masterLabel>
            <translation>GOG158/AGO-OVER-3循证研究证实TC方案毒性反应更低、更方便给药，且疗效相当</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_2_1</masterLabel>
            <translation>指南推荐：以含卡铂为基础的方案是铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_DR_2_2_2</masterLabel>
            <translation>&quot;ICON4/AGO-OVER2.2证实TC治疗铂类敏感复发性卵巢癌在总生存率和无进展生存率方面优于其它铂类方案,&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Poor effect of Metformin Generic’s low dosage</masterLabel>
            <translation><!-- Poor effect of Metformin Generic’s low dosage --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Receive</masterLabel>
            <translation><!-- Receive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_1</masterLabel>
            <translation>不满足蒽环类方案的疗效，想要追求疗效和安全性更好的方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_2</masterLabel>
            <translation>国内外指南推荐，泰素方案是早期乳腺癌辅助治疗的标准方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_3</masterLabel>
            <translation>研究表明泰素3周序贯治疗显著提高无病生存率和总生存率，且安全性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_4</masterLabel>
            <translation>泰素是首个上市的紫杉类药物，20年临床验证，疗效优越、安全性好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_5</masterLabel>
            <translation>泰素独有的植物细胞培养专利技术，稳定性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_1_6</masterLabel>
            <translation>研究表明预处理后，泰素引起的过敏反应发生率少</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_2_1</masterLabel>
            <translation>国内外指南推荐足周期的泰素方案是早期可手术乳腺癌辅助治疗的标准方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_2_2</masterLabel>
            <translation>临床研究证实足周期的泰素方案具有优越的疗效和良好的安全性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_1_3_1</masterLabel>
            <translation>泰素:达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_1</masterLabel>
            <translation>国内外指南推荐：紫衫醇联合卡铂（TC方案）作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_3</masterLabel>
            <translation>BC泰素独有的植物细胞培养专利技术，稳定性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_4</masterLabel>
            <translation>GOG158/AGO-OVER-3循证研究证实TC方案毒性反应更低、更方便给药，且疗效相当</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_5</masterLabel>
            <translation>0V16研究证实：不推荐TC方案增加顺铂/拓扑替康序贯治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_6</masterLabel>
            <translation>GOG0182-ICON5研究证实：不推荐TC方案增加第三种细胞毒药物联合或序贯治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_7</masterLabel>
            <translation>SCOTROC研究证实：晚期卵巢癌首选含紫杉醇方案，有神经系统疾病和糖尿病病史病例可选择含多西紫杉醇方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_8</masterLabel>
            <translation>LiPusu and Abraxane会被网状内皮系统吞噬和破坏</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_1_9</masterLabel>
            <translation>LiPusu 说明书中写明需要预处理</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_1</masterLabel>
            <translation>指南推荐TC方案为铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_2</masterLabel>
            <translation>ICON4/AGO-OVER2.2证实泰素联合铂类治疗铂类敏感复发性卵巢癌在总生存率和无进展生存率方面优于其它铂类方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_4</masterLabel>
            <translation>LiPusu and Abraxane被网状内皮系统吞噬和破坏</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_2_5</masterLabel>
            <translation>泰素入药单页</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_DR_2_3_1</masterLabel>
            <translation>指南推荐6-8个疗程的TC方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>The selection of medication should be minimizing the risk and severity of hypoglycemia, weight gain and FPG/PPG/HbA1c control</masterLabel>
            <translation><!-- The selection of medication should be minimizing the risk and severity of hypoglycemia, weight gain and FPG/PPG/HbA1c control --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Engagement Activities --></label>
        <lookupFilter>
            <errorMessage><!-- Engagement Activities selected must either be in Planned or In Progress Status &amp; Assigned to should be Medical. --></errorMessage>
        </lookupFilter>
        <name>Engagement_Activities_BMS_EMEA__c</name>
        <relationshipLabel><!-- Interaction Discussions (Engagement Activities) --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Entity Reference Id --></label>
        <name>Entity_Reference_Id_vod__c</name>
    </fields>
    <fields>
        <label><!-- Feedback_OTC --></label>
        <name>Feedback_BMS_OTC_CN__c</name>
        <picklistValues>
            <masterLabel>Buf_Day_FB_1</masterLabel>
            <translation>泰诺，新康泰克的广告多，患者主动要。所以比较少处方DN</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_3</masterLabel>
            <translation>认为DN效果好，品牌好，经常处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_4</masterLabel>
            <translation>认同日夜配方的优势, 经常处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_5</masterLabel>
            <translation>认为感冒药都差不多, 偶尔处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_FB_6</masterLabel>
            <translation>白加黑与日夜百服咛差不多,又便宜(一盒15片), 处方白加黑</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_1</masterLabel>
            <translation>芬必得(或散利痛)对头痛效果挺好，不经常吃的话，胃肠道副作用不常见</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_2</masterLabel>
            <translation>不接受观点, 不处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_3</masterLabel>
            <translation>BP对发热效果好，经常处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_FB_4</masterLabel>
            <translation>BP的加合配方对头痛及各种疼痛的效果好，经常处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_1</masterLabel>
            <translation>儿童百服咛和美林（或泰诺林）都是儿童首选的解热镇痛药，分别均有处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_2</masterLabel>
            <translation>儿童百服咛安全可靠，退热效果好，是儿童首选的解热镇痛药，经常处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_3</masterLabel>
            <translation>儿童百服咛不是儿童解热镇痛首选处方，不接受观念</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_FB_4</masterLabel>
            <translation>美林（或泰诺林）退热起效速度更快，持续时间更长，所以经常处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation>AUC计算卡铂剂量的方法应用起来不方便</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_1</masterLabel>
            <translation>LWMH是预防VTE的金标准</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_2</masterLabel>
            <translation>LWMH为注射剂，患者出院使用不方便</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_3</masterLabel>
            <translation>拜瑞妥是第一个NOAC，预防VTE效果好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_4</masterLabel>
            <translation>拜瑞妥手术部位常见血肿</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_5</masterLabel>
            <translation>QD给药比BID更方便，患者依从性好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_6</masterLabel>
            <translation>LWMH长期使用安全，且能医保报销</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_FB_7</masterLabel>
            <translation>艾乐妥没有和拜瑞妥直接比较的证据</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FB_Achieved</masterLabel>
            <translation><!-- FB_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FB_NOT_Achieved</masterLabel>
            <translation><!-- FB_NOT_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_1</masterLabel>
            <translation>格华止非常安全,应该长期使用,贯穿整个治疗的全程</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_2</masterLabel>
            <translation>国产品和格华止有着相当的不同,而格华止的价格本身也很便宜</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_3</masterLabel>
            <translation>格华止可能会有伤肾的问题</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_4</masterLabel>
            <translation>认为格华止一天1.5g的剂量比较大,用到一半剂量就可以</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_5</masterLabel>
            <translation>对餐后血糖无作用,如病人只有餐后高会首选拜糖平诺和龙类药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_6</masterLabel>
            <translation>肥胖超重与否不应该以目测来定,而应以BMI大等于24来界定</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_7</masterLabel>
            <translation>对于肥胖超重的病人,格华止是优于其他药物的首选用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_8</masterLabel>
            <translation>控制降低血糖和控制心血管并发症,是糖尿病治疗的基础用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_FB_9</masterLabel>
            <translation>格华止的益处不仅在降糖本身,而在控制多重心血管危险因素</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_1</masterLabel>
            <translation>ARB也有抗动脉粥样硬化的作用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_10</masterLabel>
            <translation>冠心病是卒中患者的常见并存疾病</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_11</masterLabel>
            <translation>ACEI心血管保护证据更坚实</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_12</masterLabel>
            <translation>指南推荐ACEI用于卒中二级预防</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_13</masterLabel>
            <translation>ACEI在心血管保护方面将来有可能被ARB取代</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_14</masterLabel>
            <translation>ARB在卒中一，二级预防中循证医学证据较多</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_15</masterLabel>
            <translation>ACEI降压幅度弱</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_16</masterLabel>
            <translation>蒙诺的肝肾双通道确实有优势</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_17</masterLabel>
            <translation>蒙诺能平稳降压</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_2</masterLabel>
            <translation>蒙诺的心血管保护证据不如雅施达充足</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_3</masterLabel>
            <translation>蒙诺的肾保护证据不如洛丁新</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_4</masterLabel>
            <translation>洛汀新、雅施达有新研究</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_5</masterLabel>
            <translation>由于ACEI的咳嗽问题, 导致较多的临床医生为图方便,而选用了ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_6</masterLabel>
            <translation>ACEI循证医学证据丰富且有硬终点</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_7</masterLabel>
            <translation>ACEI在指南中的地位确实比ARB高</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_8</masterLabel>
            <translation>指南推荐高危/极高危患者起始即需优选2种降压药物联合治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_FB_9</masterLabel>
            <translation>很多心血管疾病患者合并GFR下降</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NoValue</masterLabel>
            <translation><!-- NoValue --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_1</masterLabel>
            <translation>SU降糖效果较强，经验丰富</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_10</masterLabel>
            <translation>安立泽可以控制FPG、PPG和HbA1c。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_11</masterLabel>
            <translation>安立泽胃肠道副作用发生率小</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_12</masterLabel>
            <translation>SU低血糖风险高，使用不方便</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_13</masterLabel>
            <translation>安立泽降糖效果弱</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_14</masterLabel>
            <translation>SU价格便宜</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_15</masterLabel>
            <translation>指南推荐DPP－4抑制剂作为二线用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_16</masterLabel>
            <translation>安立泽自费药，价格偏贵</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_17</masterLabel>
            <translation>AGI胃肠道副作用发生率较高，使用不方便</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_2</masterLabel>
            <translation>应用SU发生低血糖的患者应换用其他低血糖发生率低的药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_3</masterLabel>
            <translation>新病人以PPG升高为主，安立泽在全面控糖的同时控制PPG效果更好，适用于新病人</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_4</masterLabel>
            <translation>对于双胍单药失效的患者,首选加用SU,因为SU与双胍作用机制不同，联合治疗降糖更佳,使用经验丰富</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_5</masterLabel>
            <translation>安立泽对心血管和B细胞有潜在的保护作用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_6</masterLabel>
            <translation>安立泽低血糖风险小，使用方便，无需调整剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_7</masterLabel>
            <translation>安立泽降糖效果与SU相似</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_8</masterLabel>
            <translation>安立泽联合双胍，降糖效果与SU联合双胍相似</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_FB_9</masterLabel>
            <translation>安立泽是新型OAD，需要建立临床经验，有尝试意愿</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_1</masterLabel>
            <translation>认为顺铂是NCCN指南的一类推荐，比卡铂更有效，临床数据更多</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_10</masterLabel>
            <translation>伯尔定?(卡铂) + 依托泊苷是SCLC的标准化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_11</masterLabel>
            <translation>伯尔定?(卡铂)/依托泊苷联合同步放疗方案治疗局限期SCLC患者总生存获益优异</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_12</masterLabel>
            <translation>对于广泛期SCLC患者， 伯尔定?(卡铂)+伊立替康也可获得优异的疗效</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_13</masterLabel>
            <translation>CA184-041 ：伯尔定?(卡铂)化疗联合伊匹单抗 序贯方案可获得显著更优的生存获益</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_14</masterLabel>
            <translation>SALUTE：伯尔定?(卡铂)化疗联合贝伐珠单抗方案可获得显著更优的PFS获益</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_15</masterLabel>
            <translation>与顺铂相比， 伯尔定?（卡铂）对肿瘤组织的选择性更高</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_16</masterLabel>
            <translation><!-- Paraplatin_FB_16 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_2</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心伯尔定的疗效劣于顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_3</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心伯尔定的安全性低于顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_4</masterLabel>
            <translation>&quot;在铂敏感型复发卵巢癌中,担心伯尔定的疗效没有超过顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_5</masterLabel>
            <translation>&quot;在铂敏感型复发卵巢癌中,担心伯尔定的安全性低于顺铂&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_6</masterLabel>
            <translation>&quot;轻视了顺铂肾毒性危险,认为肾功能正常的患者不需大量水化&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_7</masterLabel>
            <translation>认为顺铂的呕吐反应可以控制</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_8</masterLabel>
            <translation>认为顺铂的耳毒性不明显</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_FB_9</masterLabel>
            <translation>担心卡铂引起的血小板减少副反应</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_1</masterLabel>
            <translation>在乳腺癌辅助治疗中，蒽环类方案的疗效/毒性优于紫杉醇疗效/毒性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_10</masterLabel>
            <translation>国内外指南推荐：紫衫醇联合卡铂（TC方案）作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_11</masterLabel>
            <translation>泰素是首个上市的紫杉类药物，20年临床验证，疗效优越、安全性好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_12</masterLabel>
            <translation>泰素独有的植物细胞培养专利技术，稳定性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_13</masterLabel>
            <translation>GOG158/AGO-OVER-3循证研究证实TC方案毒性反应更低、更方便给药，且疗效相当</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_14</masterLabel>
            <translation>0V16研究证实：不推荐TC方案增加顺铂/拓扑替康序贯治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_15</masterLabel>
            <translation>GOG0182-ICON5研究证实：不推荐TC方案增加第三种细胞毒药物联合或序贯治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_16</masterLabel>
            <translation>SCOTROC研究证实：晚期卵巢癌首选含紫杉醇方案，有神经系统疾病和糖尿病病史病例可选择含多西紫杉醇方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_17</masterLabel>
            <translation>LiPusu and Abraxane会被网状内皮系统吞噬和破坏</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_18</masterLabel>
            <translation>LiPusu 说明书中写明需要预处理</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_19</masterLabel>
            <translation>研究表明预处理后，泰素引起的过敏反应发生率少</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_2</masterLabel>
            <translation>在乳腺癌辅助治疗中，紫杉醇方案疗效优于蒽环类方案，故常规选择紫杉醇方案辅助化疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_3</masterLabel>
            <translation>紫杉醇仿制品的疗效跟品牌没有差异性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_4</masterLabel>
            <translation>进口紫杉醇的工艺品质更高、稳定性更好，常规选择进口品牌</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_5</masterLabel>
            <translation>紫杉醇容易引起过敏反应</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_6</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心Taxol方案疗效和安全性不优于多西他赛的方案&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_7</masterLabel>
            <translation>&quot;在晚期卵巢癌中,担心Taxol方案疗效不优于力朴素/白蛋白紫杉醇的方案&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_8</masterLabel>
            <translation>Anzatax是原研紫杉醇</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_FB_9</masterLabel>
            <translation>&quot;在晚期卵巢癌中,接受力朴素无需预处理观念&quot;</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_1</masterLabel>
            <translation>TG只有25种维生素矿物质，善存有29种，所以选择处方善存。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_2</masterLabel>
            <translation>维生素和矿物质有益于慢性病三级预防，应该长期补充，经常处方。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_3</masterLabel>
            <translation>处方金额限制，很少处方TG，但经常推荐病人到药店买。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_1</masterLabel>
            <translation>TJC对儿童生长发育有益，只对营养缺乏的儿童处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_2</masterLabel>
            <translation>TJC适合儿童生长发育所需，经常处方</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_FB_1</masterLabel>
            <translation>维康福的品牌好，比国产复合维生素B多了一种B12，经常处方。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_FB_2</masterLabel>
            <translation>维康福价格贵，虽然比国产的好，但还是比较少处方。</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Incremental Shift --></label>
        <name>Incremental_Shift_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Added dosage to 1.5-2g to all T2DM patients.</masterLabel>
            <translation><!-- Added dosage to 1.5-2g to all T2DM patients. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adding Taxane (3-week) to anthracycline regimen as 1st line adjuvant chemotherapy in EBC.</masterLabel>
            <translation><!-- Adding Taxane (3-week) to anthracycline regimen as 1st line adjuvant chemotherapy in EBC. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_2</masterLabel>
            <translation>了解博路定(ETV)的疗效和耐药数据, 开始处方ETV</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_3</masterLabel>
            <translation>理解长期治疗的意义和耐药的危害,认可国内外指南对于核苷初治患者治疗推荐,在核苷初治病人中首选博路定(ETV)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_4</masterLabel>
            <translation>充分理解耐药危害和耐药通路，认可博路定（ETV)在核苷经治患者中的数据和疗效，在合适的经治病人中选择博路定(ETV)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_1_5</masterLabel>
            <translation>慢乙肝需要长期治疗，相信博路定(ETV)长期治疗可带来持续获益，长期处方博路定(ETV)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_1</masterLabel>
            <translation>认为博路定与仿制品在质量、疗效、安全性方面没有差异,从不主动处方博路定，甚至主动将博路定转换成仿制品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_2</masterLabel>
            <translation>相信博路定与仿制品在质量、疗效、安全性方面存在一定差异，对高危、难治或经济条件好的病人主动处方博路定，但对普通病人仍首选仿制品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_3</masterLabel>
            <translation>相信博路定与仿制品在质量、疗效、安全性方面存在显著差异，对所有病人均优先推荐博路定，但病人要求时会被动处方仿制品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_IS_2_4</masterLabel>
            <translation>深信使用博路定可体现其学术地位和专业形象，不接受仿制品并主动将仿制品转换为博路定</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_1</masterLabel>
            <translation>新开发医生，对于髋/膝关节术后患者，尚不完全清楚其治疗观念；或者使用LWMH预防VTE的发生</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_2</masterLabel>
            <translation>观念-对于髋/膝关节术后患者，认可需要抗凝药物预防VTE发生，口服药物方便出院使用，行为-院内使用LWMH预防VTE，出院使用拜瑞妥</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_3</masterLabel>
            <translation>观念-对于髋/膝关节术后患者，认可NOAC有效预防VTE发生，行为-70%初始首选艾乐妥，出院推荐使用1周艾乐妥</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_IS_1_4</masterLabel>
            <translation>观念-认可艾乐妥有效预防VTE发生，并不增加出血风险；行为-80%初始首选艾乐妥，出院继续艾乐妥，髋关节患者推荐使用7盒，膝关节患者推荐使用3盒</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu will be prescribed to new diagnosed T2DM patients as preferred initial therapy</masterLabel>
            <translation><!-- Glu will be prescribed to new diagnosed T2DM patients as preferred initial therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_IS_1_1</masterLabel>
            <translation>对于新诊断的2型糖尿病患者, 将格华止作为起始用药选择之一。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_1</masterLabel>
            <translation>观念-认同蒙诺作为第三代ACEI具有疗效安全性的优势，是心梗合并高血压患者首选；行为-70%以上新患者首选</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_2</masterLabel>
            <translation>观念-认同ACEI对于心梗患者具有更好的疗效，减少远期心血管事件的发生，优于ARB，是指南推荐的首选；行为-能主动将部分ARB/ACEI进行替换</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_3</masterLabel>
            <translation>观念-认为心梗合并高血压患者，ARB和ACEI都可以选择，没有什么差别，ARB可能更方便；行为-仅老病人续方为主</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_1_4</masterLabel>
            <translation>新开发医生，尚不完全清楚其治疗观念；或大量将老病人替换为其他ACEI或ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_1</masterLabel>
            <translation>观念-医生认同蒙诺作为第三代ACEI具有疗效安全性的优势，是心绞痛合并高血压需行PCI术的患者首选；行为-70%以上新患者首选；</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_2</masterLabel>
            <translation>观念-认同ACEI对于心绞痛合并高血压需行PCI术的患者具有更好的疗效，减少远期心血管事件的发生，优于ARB，是指南推荐的首选；行为-能主动将部分ARB/ACEI进行替换；</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_3</masterLabel>
            <translation>观念-认为心绞痛合并高血压需行PCI术的患者，ARB和ACEI都可以选择，没有什么差别，ARB可能更方便；行为-仅老病人续方为主</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_2_4</masterLabel>
            <translation>新开发医生，尚不完全清楚其治疗观念；或大量将老病人替换为其他ACEI或ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_1</masterLabel>
            <translation>观念-医生认同蒙诺作为第三代ACEI具有疗效安全性的优势，是心衰患者首选；行为-80%以上心衰新患者首选；</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_2</masterLabel>
            <translation>观念-认同ACEI才是心衰治疗的基石，能真正减少心衰复发及远期事件，是心衰必须的治疗；行为-能主动将部分ARB/ACEI进行替换；</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_3</masterLabel>
            <translation>观念-认为ARB和ACEI都是指南可以选择的心衰治疗药物，ARB可能更方便；行为-仅老病人续方为主；</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_3_4</masterLabel>
            <translation>新开发医生，尚不完全清楚其治疗观念；或大量将老病人替换为其他ACEI或ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_1</masterLabel>
            <translation>观念-认同蒙诺作为第三代ACEI具有疗效安全性的优势，是高血压合并冠心病患者的首选联合治疗药物；行为-门诊新诊断伴冠心病患者首选蒙诺</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_2</masterLabel>
            <translation>观念-认同ACEI对于合并冠心病的高血压患者具有更好的心脏保护作用，逆转心肌肥厚，减少远期心血管事件的发生优于ARB；行为-能主动联合使用蒙诺或替换其他ARB/ACEI；</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_3</masterLabel>
            <translation>观念-医生认为高血压患者，即便合并冠心病，降压是第一位的，首选CCB降压；行为-仅既往老病人续方为主；</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_IS_4_4</masterLabel>
            <translation>新开发医生，尚不完全清楚其治疗观念；或大量将老病人替换为其他ACEI或ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only when concern the side effect about SU or AGI,then choice Onglyza for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Only when concern the side effect about SU or AGI,then choice Onglyza for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Only when concern the side effect about SU or AGI,then choice add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Only when concern the side effect about SU or AGI,then choice add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_1_1</masterLabel>
            <translation>对所有小细胞肺癌患者，将顺铂方案作为化疗的标准治疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_1_2</masterLabel>
            <translation>对所有小细胞肺癌患者，将伯尔定?（卡铂）方案作为化疗的标准治疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_2_1</masterLabel>
            <translation>对于所有晚期卵巢癌的患者将顺铂方案作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_2_2</masterLabel>
            <translation>对于所有晚期卵巢癌患者将含伯尔定方案作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_IS_2_3</masterLabel>
            <translation>对于所有铂敏感型复发卵巢癌的患者使用伯尔定方案作为首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prescribe Glu to all T2DM patients on whole treatment.</masterLabel>
            <translation><!-- Prescribe Glu to all T2DM patients on whole treatment. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regard Onglyza as the first choice for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Regard Onglyza as the first choice for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regard Onglyza as the first choice for the patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Regard Onglyza as the first choice for the patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Regular add Onglyza on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular add SU or AGI on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above</masterLabel>
            <translation><!-- Regular add SU or AGI on Met for patient who Glucose uncontrol with mono Met dosage 1500mg above --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular use Onglyza for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Regular use Onglyza for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Regular use SU or AGI for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Regular use SU or AGI for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_1_1</masterLabel>
            <translation>对于所有早期可手术乳腺癌患者，将蒽环类方案作为辅助化疗的标准方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_1_2</masterLabel>
            <translation>对于所有早期可手术乳腺癌患者，将泰素?方案作为辅助化疗的标准方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_1_3</masterLabel>
            <translation>对于所有早期可手术乳腺癌患者，使用足周期的泰素?方案治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_1</masterLabel>
            <translation>对于所有晚期卵巢癌的患者将非TC方案作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_2</masterLabel>
            <translation>对于所有晚期卵巢癌患者将泰素联合伯尔定作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_3</masterLabel>
            <translation>对于所有铂敏感型复发卵巢癌的患者使用泰素联合伯尔定方案作为首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_IS_2_4</masterLabel>
            <translation>完成所有周期的泰素联合伯尔定化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treat CHB but not use ETV</masterLabel>
            <translation><!-- Treat CHB but not use ETV --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Indication --></label>
        <name>Indication__c</name>
        <picklistValues>
            <masterLabel>Indication 1</masterLabel>
            <translation><!-- Indication 1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Indication 2</masterLabel>
            <translation><!-- Indication 2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Indication 3</masterLabel>
            <translation><!-- Indication 3 --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Interaction Topic --></label>
        <name>Interaction_Topic_BMS__c</name>
        <picklistValues>
            <masterLabel>1- Profiling</masterLabel>
            <translation><!-- 1- Profiling --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>1-Pipeline Discussion</masterLabel>
            <translation><!-- 1-Pipeline Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2- Introduction</masterLabel>
            <translation><!-- 2- Introduction --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2-Disease Awareness</masterLabel>
            <translation><!-- 2-Disease Awareness --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3- Medical Communication Topic</masterLabel>
            <translation><!-- 3- Medical Communication Topic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4- Clinical Trial</masterLabel>
            <translation><!-- 4- Clinical Trial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Advisory Board</masterLabel>
            <translation><!-- 5- Advisory Board --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Compassionate Use Support</masterLabel>
            <translation><!-- 5- Compassionate Use Support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Congress Debrief</masterLabel>
            <translation><!-- 5- Congress Debrief --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Early Access Program (EAP)</masterLabel>
            <translation><!-- 5- Early Access Program (EAP) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Market Access Support</masterLabel>
            <translation><!-- 5- Market Access Support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Med Info Department Follow-Up</masterLabel>
            <translation><!-- 5- Med Info Department Follow-Up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Pipeline</masterLabel>
            <translation><!-- 5- Pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- RMP Related</masterLabel>
            <translation><!-- 5- RMP Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5- Speaker/Consultant Prep</masterLabel>
            <translation><!-- 5- Speaker/Consultant Prep --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ad Board Related</masterLabel>
            <translation><!-- Ad Board Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advisory Board</masterLabel>
            <translation><!-- Advisory Board --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advisory Board_cn</masterLabel>
            <translation>Advisory Board</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS Clinical Trial_cn</masterLabel>
            <translation>BMS Clinical Trail</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial</masterLabel>
            <translation><!-- Clinical Trial --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 1st Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 1st Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 2nd Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 2nd Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 3rd Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 3rd Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - 4th Qtr Visit</masterLabel>
            <translation><!-- Clinical Trial - 4th Qtr Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial - Pre Initiation / Non-Scope Related</masterLabel>
            <translation><!-- Clinical Trial - Pre Initiation / Non-Scope Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial Investigator Meeting</masterLabel>
            <translation><!-- Clinical Trial Investigator Meeting --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial Pre-Initiation Visit / Non-Scope</masterLabel>
            <translation><!-- Clinical Trial Pre-Initiation Visit / Non-Scope --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trial Visit</masterLabel>
            <translation><!-- Clinical Trial Visit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Compassionate Use Support</masterLabel>
            <translation><!-- Compassionate Use Support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Congress Debrief</masterLabel>
            <translation><!-- Congress Debrief --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Congress invitation</masterLabel>
            <translation><!-- Congress invitation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State - Proactive</masterLabel>
            <translation><!-- Disease State - Proactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State - Reactive</masterLabel>
            <translation><!-- Disease State - Reactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease State Discussion</masterLabel>
            <translation><!-- Disease State Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early Access Program (EAP)</masterLabel>
            <translation><!-- Early Access Program (EAP) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Expanded Access Program</masterLabel>
            <translation><!-- Expanded Access Program --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Formulary Discussion_cn</masterLabel>
            <translation>Formulary Discussion</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Grants Discussion</masterLabel>
            <translation><!-- Grants Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Health Outcomes</masterLabel>
            <translation><!-- Health Outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ISR Request</masterLabel>
            <translation><!-- ISR Request --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Introduction</masterLabel>
            <translation><!-- Introduction --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Investigator Sponsored Trial_cn</masterLabel>
            <translation>Investigator Sponsored Trail</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access</masterLabel>
            <translation><!-- Market Access --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access - Formulary / Slide Presentation</masterLabel>
            <translation><!-- Market Access - Formulary / Slide Presentation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access - Outcomes Research</masterLabel>
            <translation><!-- Market Access - Outcomes Research --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access - Pipeline</masterLabel>
            <translation><!-- Market Access - Pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access Discussion_cn</masterLabel>
            <translation>Market Access Discussion</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access Formulary</masterLabel>
            <translation><!-- Market Access Formulary --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Market Access Related</masterLabel>
            <translation><!-- Market Access Related --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Med Info Department Follow-Up</masterLabel>
            <translation><!-- Med Info Department Follow-Up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Med Info Dept. Follow Up</masterLabel>
            <translation><!-- Med Info Dept. Follow Up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Med Info follow-up_cn</masterLabel>
            <translation>Med Info follow-up</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Strategy Discussion</masterLabel>
            <translation><!-- Medical Strategy Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Patient Access Program</masterLabel>
            <translation><!-- Patient Access Program --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pipeline</masterLabel>
            <translation><!-- Pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pipeline (Non-Market Access)</masterLabel>
            <translation><!-- Pipeline (Non-Market Access) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product - Proactive</masterLabel>
            <translation><!-- Product - Proactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product - Reactive</masterLabel>
            <translation><!-- Product - Reactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Product Discussion</masterLabel>
            <translation><!-- Product Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Profiling</masterLabel>
            <translation><!-- Profiling --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Publication Strategy</masterLabel>
            <translation><!-- Publication Strategy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Publication_cn</masterLabel>
            <translation>Publication</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SA on Demand</masterLabel>
            <translation><!-- SA on Demand --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific Data Exchange</masterLabel>
            <translation><!-- Scientific Data Exchange --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific Exchange_cn</masterLabel>
            <translation>Scientific Exchange</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Scientific Profiling</masterLabel>
            <translation><!-- Scientific Profiling --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Evaluation</masterLabel>
            <translation><!-- Speaker Evaluation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training</masterLabel>
            <translation><!-- Speaker Training --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training - Evaluation</masterLabel>
            <translation><!-- Speaker Training - Evaluation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training - Formal</masterLabel>
            <translation><!-- Speaker Training - Formal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training - Informal</masterLabel>
            <translation><!-- Speaker Training - Informal --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker Training_cn</masterLabel>
            <translation>Speaker Training</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Speaker/Consultant Prep</masterLabel>
            <translation><!-- Speaker/Consultant Prep --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Thought Leader Profiling_cn</masterLabel>
            <translation>Thought Leader Profiling</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>iPlan Program</masterLabel>
            <translation><!-- iPlan Program --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Interaction Type --></label>
        <name>Interaction_Type_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Proactive</masterLabel>
            <translation><!-- Proactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_BARACLUDE</masterLabel>
            <translation>Proactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_BYETTA</masterLabel>
            <translation>Proactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_Eliquis</masterLabel>
            <translation>Proactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_FORXIGA</masterLabel>
            <translation>Proactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_ONGLYZA</masterLabel>
            <translation>Proactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_ORENCIA</masterLabel>
            <translation>Proactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Proactive_SPRYCEL</masterLabel>
            <translation>Proactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive</masterLabel>
            <translation><!-- Reactive --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_BARACLUDE</masterLabel>
            <translation>Reactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_BYETTA</masterLabel>
            <translation>Reactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_Eliquis</masterLabel>
            <translation>Reactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_FORXIGA</masterLabel>
            <translation>Reactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_ONGLYZA</masterLabel>
            <translation>Reactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_ORENCIA</masterLabel>
            <translation>Reactive</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactive_SPRYCEL</masterLabel>
            <translation>Reactive</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Is Achieved ? --></label>
        <name>Is_Achieved_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>No</masterLabel>
            <translation><!-- No --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Yes</masterLabel>
            <translation><!-- Yes --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Is Parent Call? --></label>
        <name>Is_Parent_Call_vod__c</name>
    </fields>
    <fields>
        <label><!-- Key Messages --></label>
        <name>Key_Messages_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>50 years experience, body weight neutral, rare hypoglycemia</masterLabel>
            <translation><!-- 50 years experience, body weight neutral, rare hypoglycemia --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Already Achieved：Protect you today, for the future outcome</masterLabel>
            <translation><!-- Already Achieved：Protect you today, for the future outcome --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM380</masterLabel>
            <translation><!-- CN_KM380 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM381</masterLabel>
            <translation><!-- CN_KM381 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM382</masterLabel>
            <translation><!-- CN_KM382 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM383</masterLabel>
            <translation><!-- CN_KM383 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM384</masterLabel>
            <translation><!-- CN_KM384 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM385</masterLabel>
            <translation><!-- CN_KM385 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM386</masterLabel>
            <translation><!-- CN_KM386 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM387</masterLabel>
            <translation><!-- CN_KM387 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM389</masterLabel>
            <translation><!-- CN_KM389 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM390</masterLabel>
            <translation><!-- CN_KM390 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM391</masterLabel>
            <translation><!-- CN_KM391 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM393</masterLabel>
            <translation><!-- CN_KM393 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM395</masterLabel>
            <translation><!-- CN_KM395 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM396</masterLabel>
            <translation><!-- CN_KM396 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM397</masterLabel>
            <translation><!-- CN_KM397 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM400</masterLabel>
            <translation><!-- CN_KM400 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM401</masterLabel>
            <translation><!-- CN_KM401 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM402</masterLabel>
            <translation><!-- CN_KM402 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM403</masterLabel>
            <translation><!-- CN_KM403 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM404</masterLabel>
            <translation><!-- CN_KM404 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM405</masterLabel>
            <translation><!-- CN_KM405 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM406</masterLabel>
            <translation><!-- CN_KM406 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM407</masterLabel>
            <translation><!-- CN_KM407 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM409</masterLabel>
            <translation><!-- CN_KM409 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_KM410</masterLabel>
            <translation><!-- CN_KM410 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_1_1</masterLabel>
            <translation>艾乐妥®显著降低髋膝关节置换术后VTE风险，且不增加出血风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_1_2</masterLabel>
            <translation>艾乐妥优化口服给药，一天两次，提供更佳的疗效与安全性平衡</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_2_1</masterLabel>
            <translation>ACC9指南推荐艾乐妥作为THR/TKR术后VTE预防优选的一种口服抗凝药。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_2_2</masterLabel>
            <translation>艾乐妥是第一个术后12-24小时起始给药的新型口服抗凝药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_2_3</masterLabel>
            <translation>艾乐妥口服给药，方便患者住院和出院连续治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_3_1</masterLabel>
            <translation>ACC9指南认为当阿哌沙班不可获得时，再考虑更换利伐沙班</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_3_2</masterLabel>
            <translation>ACCP9中与LMWH相比，每治疗1000例患者，利伐沙班减少5例DVT，但获益被同时增加的9例严重出血抵消，而阿哌沙班减少7例DVT，不增加严重出血</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_3_3</masterLabel>
            <translation>有多种代谢途径，约27%的药物通过肾脏清除，肾脏负担小</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1_4_1</masterLabel>
            <translation>达成目标：首选艾乐妥预防VTE，THR患者推荐为35天(7盒)，TKR患者为14天(3盒)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Evidence demonstrate that long term treatement with Glucophage provide Long-term benefit</masterLabel>
            <translation><!-- Evidence demonstrate that long term treatement with Glucophage provide Long-term benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage effective on FPG, PPG and HbA1c</masterLabel>
            <translation><!-- Glucophage effective on FPG, PPG and HbA1c --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage optimal dosage (2000mg / day) achieve maximum efficacy and lowest side effect</masterLabel>
            <translation><!-- Glucophage optimal dosage (2000mg / day) achieve maximum efficacy and lowest side effect --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucophage provide long-term cardiovascular protection, improve the quality of life and reduce mortality</masterLabel>
            <translation><!-- Glucophage provide long-term cardiovascular protection, improve the quality of life and reduce mortality --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guideline recommend Glucophage as the only initial therapy for new diagnosed T2DM patients</masterLabel>
            <translation><!-- Guideline recommend Glucophage as the only initial therapy for new diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_1_1</masterLabel>
            <translation>蒙诺是第三代含膦酸基的双通道代偿代谢的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_2_1</masterLabel>
            <translation>指南和临床路径推荐ACEI作为伴心梗必要治疗措施改善预后</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_2_2</masterLabel>
            <translation>ACEI作用于RAS第一轴和第二轴，产生与ARB不同的RAS抑制结果</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_3_1</masterLabel>
            <translation>FAMIS研究证实蒙诺减少心梗患者34.7%死亡及中重度心衰发生风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_3_2</masterLabel>
            <translation>RCT和RWS证实蒙诺是更好心脏保护及更高依从性第三代ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_1_3_3</masterLabel>
            <translation>2012KDIGO指南证实蒙诺真正双通道代谢。中国人PK/PD一致，靶剂量保护充分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_1_1</masterLabel>
            <translation>蒙诺是第三代含膦酸基的双通道代偿代谢的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_2_1</masterLabel>
            <translation>指南和临床路径推荐ACEI作为伴心绞痛患者必要措施，减少心梗、心衰及心源性死亡风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_2_2</masterLabel>
            <translation>ACEI作用于RAS第一轴和第二轴，产生与ARB不同的RAS抑制结果</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_3_1</masterLabel>
            <translation>FACTS显示蒙诺减少PAI-1稳定不稳定斑块，PHYLLIS证实蒙诺显著抗动脉粥样硬化</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_3_2</masterLabel>
            <translation>RCT和RWS证实蒙诺是更好心脏保护及更高依从性第三代ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_2_3_3</masterLabel>
            <translation>2012KDIGO指南证实蒙诺真正双通道代谢。中国人PK/PD一致，靶剂量保护充分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_1_1</masterLabel>
            <translation>蒙诺是第三代含膦酸基的双通道代偿代谢的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_2_1</masterLabel>
            <translation>2012版欧洲心衰指南强化了ACEI作为心衰治疗基石的推荐</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_2_2</masterLabel>
            <translation>ARB只是作为ACE抑制剂不能耐受的替代治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_2_3</masterLabel>
            <translation>ACEI全面调节RAS/缓激肽系统，改善心肌重构优于ARB</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_3_1</masterLabel>
            <translation>FEST研究证实蒙诺10-40mg/d有效且安全，VA研究证实14万例美国HF使用蒙诺较卡托普利降低26%死亡风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_3_2</masterLabel>
            <translation>RCT和RWS证实蒙诺是更好心脏保护及更高依从性第三代ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_3_3</masterLabel>
            <translation>2012KDIGO指南证实蒙诺真正双通道代谢。中国人PK/PD一致，靶剂量保护充分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_3_4_1</masterLabel>
            <translation>蒙诺是第三代含膦酸基的双通道代偿代谢的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_2_1</masterLabel>
            <translation>ACEI全面抑制RAS第一轴与第二轴，额外显著减少高血压全因死亡风险10%</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_2_2</masterLabel>
            <translation>对已使用CCB降压的合并冠心病患者，ACEI是冠心病治疗药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_2_3</masterLabel>
            <translation>CCB联合ACEI是符合最新指南思想的优选冠心病患者降压方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_3_1</masterLabel>
            <translation>更强心脏保护：蒙诺联合CCB更强降压，降低PAI-1，改善血压节律控制晨峰血压、减少CCB水肿</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_3_2</masterLabel>
            <translation>RCT和RWS证实蒙诺是更好心脏保护及更高依从性第三代ACEI2012KDIGO指南证实蒙诺真正双通道代谢。中国人PK/PD一致，靶剂量保护充分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KeyMsg_4_3_3</masterLabel>
            <translation>2012KDIGO指南证实蒙诺真正双通道代谢。中国人PK/PD一致，靶剂量保护充分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_1_1</masterLabel>
            <translation>安立泽全面控制血糖的3个关键指标（HbA1c，FPG，PPG）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_1_2</masterLabel>
            <translation>一项头对头比较安立泽与磺脲疗效研究显示与双胍联合磺脲相比，双胍联合安立泽疗效相当，低血糖风险显著降低，不增加体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_1_3</masterLabel>
            <translation>安立泽安全性与安慰剂相似</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_2_3</masterLabel>
            <translation>一天一次口服方便，无需调整剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_3_1</masterLabel>
            <translation>全面控制血糖的3大血糖关键指标（HbA1c，FPG，PPG）降糖疗效和磺脲相似且安全性良好，低血糖发生率低不增加体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_1_3_3</masterLabel>
            <translation>潜在心血管保护</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_2_1_1</masterLabel>
            <translation>全新双重机制</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_2_1_2</masterLabel>
            <translation>全面控制血糖的3大血糖关键指标（HbA1c，FPG，PPG）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KeyMsg_2_1_3</masterLabel>
            <translation>安全性良好，低血糖发生率低不增加体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_1</masterLabel>
            <translation>NCCN指南推荐伯尔定?(卡铂)方案 是SCLC的标准一线化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_2</masterLabel>
            <translation>与顺铂方案相比，伯尔定?(卡铂)方案可获得相似的生存获益</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_3</masterLabel>
            <translation>与顺铂相比，伯尔定?(卡铂)的药代动力学更有利</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_4</masterLabel>
            <translation>与顺铂方案相比，伯尔定?(卡铂)方案的肾毒性、胃肠道毒性等不良事件发生率显著更低</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_5</masterLabel>
            <translation>与顺铂不同，伯尔定?（卡铂）利用AUC通过Carvert公式计算个体化给药剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_1_6</masterLabel>
            <translation>与顺铂相比，伯尔定?（卡铂）更具便捷性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1_2_1</masterLabel>
            <translation>伯尔定?(卡铂):达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_1_1</masterLabel>
            <translation>紫杉醇联合卡铂（TC方案）作为晚期卵巢癌首选化疗方案，倍受各大权威指南推荐</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_1_2</masterLabel>
            <translation>TC方案取代TP（紫杉醇联合顺铂）方案成为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_2_1</masterLabel>
            <translation>指南推荐：以含卡铂为基础的方案是铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2_2_2</masterLabel>
            <translation>众多研究证实含铂类为基础的方案是铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_1</masterLabel>
            <translation>泰素是首个上市的紫杉类药物，20年临床验证，疗效优越、安全性好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_2</masterLabel>
            <translation>泰素独有的植物细胞培养专利技术，稳定性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_3</masterLabel>
            <translation>泰素?方案是乳腺癌辅助治疗的优选方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_1_4</masterLabel>
            <translation>泰素?3周序贯治疗显著提高无病生存率和总生存率，且安全性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_2_1</masterLabel>
            <translation>泰素?足周期的化疗方案，具有良好的治疗效果和安全性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1_3_1</masterLabel>
            <translation>泰素:达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_1_3</masterLabel>
            <translation>紫杉醇联合卡铂（TC方案）作为晚期卵巢癌首选化疗方案，倍受各大权威指南推荐</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_1_4</masterLabel>
            <translation>OV16/GOG0182-ICON5证实: TC方案是晚期卵巢癌的首选双药化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_2_3</masterLabel>
            <translation>指南推荐TC方案为铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_2_4</masterLabel>
            <translation>ICON4/AGO-OVER2.2证实：TC方案为铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2_3_1</masterLabel>
            <translation>指南推荐6-8个疗程的TC方案</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Key_Messages OTC --></label>
        <name>Key_Messages_OTC_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Baraclude_KM_1</masterLabel>
            <translation>有了医保，博路定与仿制品的价格差异大大减少，患者可以从一开始就选择博路定，原来只能承受ETV的病人现在可以换用博路定</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_10</masterLabel>
            <translation>医保用药——代表博路定（ETV）是一种专家/政府认可，治疗必须的药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_11</masterLabel>
            <translation>医保大大降低病人自付费用，原来只能承担ADV甚至LVD的患者现在可以承担博路定，并可减少后续治疗的经济负担</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_12</masterLabel>
            <translation>博路定为核苷初治患者提供强效和低耐药的双重保护</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_13</masterLabel>
            <translation>慢乙肝治疗抗病毒是关键</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_14</masterLabel>
            <translation>耐药是长期治疗一大障碍,预防耐药是最佳策略</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_15</masterLabel>
            <translation>核苷初治是使用博路定的最佳时机，第一时间，第一选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_16</masterLabel>
            <translation>耐药是昂贵的，博路定是物有所值之选</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_17</masterLabel>
            <translation>博路定与ADV无交叉耐药，在ADV经治患者中仍可保持强效</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_18</masterLabel>
            <translation>博路定长期治疗可带来组织学改善</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_2</masterLabel>
            <translation>有了医保，博路定的续方病人更可以坚持长期治疗，提高依从性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_3</masterLabel>
            <translation>恩替卡韦已进入国家医保，进入地方医保指日可待</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_4</masterLabel>
            <translation>坚持使用博路定，以后的治疗费用只会更低（针对续方）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_5</masterLabel>
            <translation>现在先用博路定，以后的治疗费用只会更低（针对核苷初治）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_6</masterLabel>
            <translation>博路定与仿制品在品质、证据和专业服务方面均存在明显差异，是您治疗乙肝真正十拿九稳的信心之选</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_7</masterLabel>
            <translation>处方博路定，充分彰显您的学术地位和专业形象</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_8</masterLabel>
            <translation>博路定与仿制品存在差异，高危、难治（应答不佳）或经济条件特别好的病人如使用仿制品可能会带来不必要的风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Baraclude_KM_9</masterLabel>
            <translation>博路定，确保治疗的成功</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_1</masterLabel>
            <translation>DN - 独特日夜配方，日片不嗜睡，更适合白领、教师、学生、医生和工人等需在白天正常工作生活的人群；夜片可安睡，让患者轻松享受自由生活</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_2</masterLabel>
            <translation>DN - 每片含对乙酰氨基酚500mg，解热镇痛效果更佳</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_3</masterLabel>
            <translation>DN - 所有感冒症状中，各种疼痛对患者正常工作生活的影响最明显，应选择镇痛效果更好的对症治疗药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_4</masterLabel>
            <translation>DN - 与新康泰克蓝色装(缓释胶囊）相比,白天不嗜睡,更有止咳和退热作用。 （新康泰克蓝色装不含解热镇痛和止咳成分）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_5</masterLabel>
            <translation>DN - 感冒起病48小时内，各种疼痛症状(肌肉酸痛、头痛、咽痛)发生率最高，其次为卡他症状(鼻塞、流涕和喷嚏)，应尽早采取全面对症治疗方案，全面有效缓解各种感冒核心症状</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Day_KM_6</masterLabel>
            <translation>DN - 含有四种药物成分，可有效缓解因感冒引起的各种疼痛、发热、卡他及咳嗽等常见症状</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_1</masterLabel>
            <translation>BP - 加合百服咛镇痛效果15分钟起效，持续镇痛4-6小时</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_2</masterLabel>
            <translation>BP - 权威指南推荐对乙酰氨基酚+咖啡因复合配方为中轻度偏头痛一线用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_3</masterLabel>
            <translation>BP - 除各种头痛外，加合百服咛还能有效缓解牙痛、女性痛经和神经痛</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_4</masterLabel>
            <translation>BP - 对乙酰氨基酚对胃肠道无刺激，患者依从性更高</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Buf_Plus_KM_5</masterLabel>
            <translation>BP - 对乙酰氨基酚+咖啡因镇痛效果优于单方对乙酰氨基酚，更少的对乙酰氨基酚用量，获得更好的镇痛疗效</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_KM_1</masterLabel>
            <translation>发热危害儿童健康，如不及时正确的处理容易造成热惊厥等严重后果</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_KM_2</masterLabel>
            <translation>儿童百服咛退热系列 - 对乙酰氨基酚是儿童百服宁退热系列的主要成分，它是WHO推荐的安全有效的儿童退热药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Children_KM_3</masterLabel>
            <translation>儿童百服咛退热系列 - 对乙酰氨基酚与布洛芬退热效果相当，且直接作用于疼痛中枢,对肠胃刺激小，比布洛芬更安全</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_1</masterLabel>
            <translation>艾乐妥抗凝1+1，安度围术期</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_2</masterLabel>
            <translation>艾乐妥®显著降低髋膝关节置换术后VTE风险，且不增加出血风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_3</masterLabel>
            <translation>艾乐妥优化口服给药，一天两次，提供更佳的疗效与安全性平衡</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_4</masterLabel>
            <translation>ACC9指南推荐艾乐妥作为THR/TKR术后VTE预防优选的一种口服抗凝药。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_5</masterLabel>
            <translation>艾乐妥口服给药，方便患者住院和出院连续治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_KM_6</masterLabel>
            <translation>艾乐妥早一粒晚一粒，血药浓度更平稳，提高抗凝</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_1</masterLabel>
            <translation>指南推荐格华止是新诊断患者的首选，并贯穿始终。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_2</masterLabel>
            <translation>全面降糖，同时降低基础和餐后血糖 ，控制体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_3</masterLabel>
            <translation>出色的心血管保护，减少终点事件和死亡率，证据来自于最佳的剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_4</masterLabel>
            <translation>格华止联合胰岛素，降低低血糖风险</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_5</masterLabel>
            <translation>格华止联合胰岛素，降低大血管并发症的风险，减少死亡率</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_6</masterLabel>
            <translation>格华止联合胰岛素，有效控制体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_7</masterLabel>
            <translation>降糖疗效与用药剂量呈正相关，2000mg效果最佳</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_KM_8</masterLabel>
            <translation>格华止联合胰岛素，比单用胰岛素更有效降糖</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_1</masterLabel>
            <translation>蒙诺心、肾保护证据全面的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_2</masterLabel>
            <translation>蒙诺心血管保护证据可靠的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_3</masterLabel>
            <translation>蒙诺24小时平稳降压,真正一天一次的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_4</masterLabel>
            <translation>蒙诺真正肝肾双通道代偿排泄的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_5</masterLabel>
            <translation>蒙诺真正肝肾双通道代偿排泄，肾功能不全患者无需调整剂量的ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_6</masterLabel>
            <translation>联合ACEI是优选的降压方案之一</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_7</masterLabel>
            <translation>ACEI是高血压合并冠心病;慢性心衰治疗的基石</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_KM_8</masterLabel>
            <translation>冠心病是卒中患者的并存疾病，无论是否存在冠心病史</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Value</masterLabel>
            <translation><!-- No Value --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_1</masterLabel>
            <translation>安立泽安全性与安慰剂相似</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_2</masterLabel>
            <translation>一天一次口服方便，无需调整剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_3</masterLabel>
            <translation>安全性良好，低血糖发生率低不增加体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_4</masterLabel>
            <translation>全面控制血糖的3大血糖关键指标（HbA1c，FPG，PPG）降糖疗效和磺脲相似且安全性良好，低血糖发生率低不增加体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_5</masterLabel>
            <translation>一项头对头比较安立泽与磺脲疗效研究显示与双胍联合磺脲相比，双胍联合安立泽疗效相当，低血糖风险显著降低，不增加体重</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_6</masterLabel>
            <translation>全新双重机制</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_7</masterLabel>
            <translation>安立泽全面控制血糖的3个关键指标（HbA1c，FPG，PPG）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_KM_8</masterLabel>
            <translation>潜在心血管保护</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_1</masterLabel>
            <translation>NCCN指南推荐伯尔定?(卡铂)方案 是SCLC的标准一线化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_10</masterLabel>
            <translation>众多研究证实含铂类为基础的方案是铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_2</masterLabel>
            <translation>与顺铂方案相比，伯尔定?(卡铂)方案可获得相似的生存获益</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_3</masterLabel>
            <translation>与顺铂相比，伯尔定?(卡铂)的药代动力学更有利</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_4</masterLabel>
            <translation>与顺铂方案相比，伯尔定?(卡铂)方案的肾毒性、胃肠道毒性等不良事件发生率显著更低</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_5</masterLabel>
            <translation>与顺铂不同，伯尔定?（卡铂）利用AUC通过Carvert公式计算个体化给药剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_6</masterLabel>
            <translation>与顺铂相比，伯尔定?（卡铂）更具便捷性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_7</masterLabel>
            <translation>紫杉醇联合卡铂（TC方案）作为晚期卵巢癌首选化疗方案，倍受各大权威指南推荐</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_8</masterLabel>
            <translation>TC方案取代TP（紫杉醇联合顺铂）方案成为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_KM_9</masterLabel>
            <translation>指南推荐：以含卡铂为基础的方案是铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_1</masterLabel>
            <translation>安全耐受，不良反应易于管理</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_2</masterLabel>
            <translation>服用方便，依从性好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_3</masterLabel>
            <translation>对各期CML均可强效、迅速达到缓解，并显著延长生存期</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL_KM_4</masterLabel>
            <translation>全新分子结构强效、广泛抑制BCR-ABL和SRC家族激酶，抑制突变谱广</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_1</masterLabel>
            <translation>泰素是首个上市的紫杉类药物，20年临床验证，疗效优越、安全性好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_2</masterLabel>
            <translation>泰素独有的植物细胞培养专利技术，稳定性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_3</masterLabel>
            <translation>泰素?方案是乳腺癌辅助治疗的优选方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_4</masterLabel>
            <translation>泰素?3周序贯治疗显著提高无病生存率和总生存率，且安全性更好</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_5</masterLabel>
            <translation>泰素?足周期的化疗方案，具有良好的治疗效果和安全性</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_6</masterLabel>
            <translation>紫杉醇联合卡铂（TC方案）作为晚期卵巢癌首选化疗方案，倍受各大权威指南推荐</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_7</masterLabel>
            <translation>OV16/GOG0182-ICON5证实: TC方案是晚期卵巢癌的首选双药化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_8</masterLabel>
            <translation>指南推荐TC方案为铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_KM_9</masterLabel>
            <translation>ICON4/AGO-OVER2.2证实：TC方案为铂敏感型复发型卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_1</masterLabel>
            <translation>TG- 循证医学证据显示，补充多种维生素微量元素能有效降低各种慢性病患者的死亡率</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_2</masterLabel>
            <translation>TG - 金施尔康含有12种维生素和13种微量元素，是预防和治疗体内维生素矿物质缺乏的理想之选</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_3</masterLabel>
            <translation>TG - 金施尔康除含有更多的B族维生素，更有助于血管神经病变的恢复和治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_4</masterLabel>
            <translation>TG- 循证医学证据显示，补充多种维生素矿物质，可有效减少各类慢性疾病并发症的发生和发展</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_5</masterLabel>
            <translation>TG - 控制并发症、提高患者生存率和生活质量，是慢性疾病三级预防的主要目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_6</masterLabel>
            <translation>TG - 慢性病是导致死亡的首要原因，由慢性病造成的死亡约占所有死亡的60%</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_G_KM_7</masterLabel>
            <translation>TG- 循证医学证据显示，补充多种维生素矿物质，可有效减少药物引起的不良反应，改善预后症状，提高慢性病患者生活质量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_KM_1</masterLabel>
            <translation>TJC - 含10种维生素(VA, VD, VB1, VB2, VB6, VB12, 烟酰胺，VC, VE，叶酸)，有效改善腹泻、反复呼吸道感染等儿童常见疾病。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Theragran_JR_KM_2</masterLabel>
            <translation>TJC - 多种维生素帮助防治儿童营养性贫血。《儿童缺铁和缺铁性贫血防治建议》指出补铁时可同时补充VC及其他维生素。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_1</masterLabel>
            <translation>Bco - 国内配方最完整的复合维生素B;含6种B族维生素(B1,B2,B6,B12,泛酸，烟酰胺）,配比科学,符合我国营养学会的推荐量(DRIs),而国产复合维生素B含量达不到DRIs要求。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_2</masterLabel>
            <translation>Bco - 国内唯一添加维生素B12的复合维生素B;独有进口B12性能更稳定防治更全面:参与同型半胱氨酸代谢,维持神经系统发挥正常功能,参与红细胞中的DNA合成。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_3</masterLabel>
            <translation>Bco - 各种B族维生素协同作用,助益心血管,糖尿病,神经病变,眼科及皮肤粘膜疾病的治疗。</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VB_Complex_KM_4</masterLabel>
            <translation>Bco - 一天一粒服用方便，患者依从性好，国产复B一天服用三到四次,依从性差。</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Key Topic --></label>
        <name>Key_Topics_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>Brand&apos;s key messages</masterLabel>
            <translation><!-- Brand&apos;s key messages --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Brand&apos;s perception</masterLabel>
            <translation><!-- Brand&apos;s perception --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trials</masterLabel>
            <translation><!-- Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Company&apos;s perception</masterLabel>
            <translation><!-- Company&apos;s perception --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Compassionate Use Program</masterLabel>
            <translation><!-- Compassionate Use Program --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Compound-related question</masterLabel>
            <translation><!-- Compound-related question --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Congress</masterLabel>
            <translation><!-- Congress --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion on 3rd party tactics and sponsorship</masterLabel>
            <translation><!-- Discussion on 3rd party tactics and sponsorship --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease Area / Therapy Area Discussion</masterLabel>
            <translation><!-- Disease Area / Therapy Area Discussion --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Grants</masterLabel>
            <translation><!-- Grants --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Guidelines &amp; Therapeutic protocols on specific Disease</masterLabel>
            <translation><!-- Guidelines &amp; Therapeutic protocols on specific Disease --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IST&apos;s</masterLabel>
            <translation><!-- IST&apos;s --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Interventional Studies</masterLabel>
            <translation><!-- Interventional Studies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Publications</masterLabel>
            <translation><!-- Publications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Surveys</masterLabel>
            <translation><!-- Surveys --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- MSL Type --></label>
        <name>MSL_Type_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Material --></label>
        <name>Material_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>CN_PM1405</masterLabel>
            <translation><!-- CN_PM1405 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1406</masterLabel>
            <translation><!-- CN_PM1406 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1408</masterLabel>
            <translation><!-- CN_PM1408 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1412</masterLabel>
            <translation><!-- CN_PM1412 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1413</masterLabel>
            <translation><!-- CN_PM1413 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1416</masterLabel>
            <translation><!-- CN_PM1416 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1423</masterLabel>
            <translation><!-- CN_PM1423 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1424</masterLabel>
            <translation><!-- CN_PM1424 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1425</masterLabel>
            <translation><!-- CN_PM1425 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CN_PM1430</masterLabel>
            <translation><!-- CN_PM1430 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA: Glucophage protect you all the time</masterLabel>
            <translation><!-- DA: Glucophage protect you all the time --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA:Glucophage is the only initial therapy In new diagnosed T2DM patient</masterLabel>
            <translation><!-- DA:Glucophage is the only initial therapy In new diagnosed T2DM patient --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA:Optimal dosage (2000mg / day) achieve best hypoglycemic effect and cardiovascular benefit</masterLabel>
            <translation><!-- DA:Optimal dosage (2000mg / day) achieve best hypoglycemic effect and cardiovascular benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_1_1</masterLabel>
            <translation>DA-艾乐妥抗凝1+1，客户观念深访</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_1_2</masterLabel>
            <translation>视频：艾乐妥视频</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_2_1</masterLabel>
            <translation>DA-阿哌沙班优化口服给药，优化抗凝</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_2_2</masterLabel>
            <translation>抽印本：ADVANCE髋关节</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_2_3</masterLabel>
            <translation>抽印本：ADVANCE膝关节</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_3_1</masterLabel>
            <translation>DA-艾乐妥助您的患者安度围术期</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_3_2</masterLabel>
            <translation>幻灯：艾乐妥介绍</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_3_3</masterLabel>
            <translation>幻灯：艾乐妥临床研究介绍</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1_4_1</masterLabel>
            <translation>达成目标：首选艾乐妥预防VTE，THR患者推荐为35天(7盒)，TKR患者为14天(3盒)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_Achieved</masterLabel>
            <translation><!-- Glu_MT_Achieved --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_1_1</masterLabel>
            <translation>蒙诺DA+客户观念深访</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_1</masterLabel>
            <translation>抽印本：RAS系统再认识</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_2</masterLabel>
            <translation>抽印本：ACEI心血管一线保护药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_3</masterLabel>
            <translation>DA插页：专家之选-蒙诺心梗伴高血压患者长期用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_4</masterLabel>
            <translation>幻灯：专家讲稿-ACEI新机制认识（廖玉华）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_5</masterLabel>
            <translation>视频：蒙诺品牌视频</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_2_6</masterLabel>
            <translation>心梗临床路径挂图应用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_1</masterLabel>
            <translation>抽印本：医学论坛报-从最新研究看伴CKD患者ACEI选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_3</masterLabel>
            <translation>DA插页：专家之选-蒙诺第三代ACEI</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_4</masterLabel>
            <translation>DA插页：专家之选-蒙诺RCT&amp;RWS证据</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_5</masterLabel>
            <translation>DA插页：专家之选-重视中国患者ACEI选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_6</masterLabel>
            <translation>幻灯：临床路径系列+蒙诺作用特点</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_7</masterLabel>
            <translation>视频：ACEI发展史/蒙诺肝肾双通道机理</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1_3_8</masterLabel>
            <translation>心梗临床路径查房本应用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_2_3</masterLabel>
            <translation>幻灯：专家讲稿-2012Frank外国专家巡讲幻灯</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_2_5</masterLabel>
            <translation>DA插页：专家之选-冠心病页指南部分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_2_6</masterLabel>
            <translation>心绞痛临床路径挂图应用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2_3_1</masterLabel>
            <translation>蒙诺研究：PAI-1研究/PHYLLIS研究</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_1</masterLabel>
            <translation>DA插页：专家之选-心衰治疗基石-指南部分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_3</masterLabel>
            <translation>幻灯：ACEI心血管一线保护药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_4</masterLabel>
            <translation>幻灯：专家讲稿-ACEI/ARB 在2012版欧洲心衰指南比较（蒋文平）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_2_5</masterLabel>
            <translation>急性心衰临床路径挂图应用</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_3_1</masterLabel>
            <translation>抽印本：几种ACEI对心衰死亡率的影响</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3_3_2</masterLabel>
            <translation>DA插页：专家之选-心衰治疗基石</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_1</masterLabel>
            <translation>抽印本：ACEI减少高血压患者死亡</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_2</masterLabel>
            <translation>抽印本：为什么ACEI能够减少高血压患者死亡</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_3</masterLabel>
            <translation>DA：专家之选-冠心病优化治疗-指南部分</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_4</masterLabel>
            <translation>幻灯片: 蒙诺-优化冠心病患者治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_2_5</masterLabel>
            <translation>幻灯片：ACEI心血管病一线治疗药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_3_1</masterLabel>
            <translation>DA插页：专家之选-伴冠心病优化治疗/24h平稳降压</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_4_3_6</masterLabel>
            <translation>幻灯：专家之选-蒙诺用于高血压治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_Achlved</masterLabel>
            <translation>达成目标：Protect you today, for the future outcome</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_1_1</masterLabel>
            <translation>DA: 安立泽-安心降糖，立刻选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_1_2</masterLabel>
            <translation>DT Slides：安心降糖，立刻选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_1_3</masterLabel>
            <translation>Reprint：沙格列汀综述、001试验</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Onglyza_MT_1_3_3</masterLabel>
            <translation>Reprint：001试验、CV outcome</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_1</masterLabel>
            <translation>DA:以伯尔定（卡铂）为基础的化疗方案--小细胞肺癌SCLC的标准一线化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_2</masterLabel>
            <translation>Slides:以伯尔定（卡铂）为基础的化疗方案--小细胞肺癌SCLC的标准一线化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_3</masterLabel>
            <translation>DA：原研进口卡铂注射液（伯尔定?）较顺铂更具优势的二代铂类药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_1_4</masterLabel>
            <translation>slides：原研进口卡铂注射液（伯尔定?）较顺铂更具优势的二代铂类药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1_2_1</masterLabel>
            <translation>伯尔定（卡铂）:达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_1_1</masterLabel>
            <translation>DA:泰素联合伯尔定作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_1_2</masterLabel>
            <translation>Slides:泰素联合伯尔定作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_1_3</masterLabel>
            <translation>Slides:2013年NCCN指南解读</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_2_1</masterLabel>
            <translation>DA:泰素联合伯尔定作为铂敏感型复发卵巢癌的首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2_2_2</masterLabel>
            <translation>Slides:泰素联合伯尔定作为铂敏感型复发卵巢癌的首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slides:Global and domestic Diabetes Guideline</masterLabel>
            <translation><!-- Slides:Global and domestic Diabetes Guideline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slides:Gold standard of Metformin</masterLabel>
            <translation><!-- Slides:Gold standard of Metformin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Slides:Which can provide CV protection for T2DM patients.</masterLabel>
            <translation><!-- Slides:Which can provide CV protection for T2DM patients. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_1</masterLabel>
            <translation>DA:泰素?  乳腺癌辅助治疗的“基石”</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_2</masterLabel>
            <translation>Slides:泰素? 乳腺癌辅助治疗的“基石”</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_3</masterLabel>
            <translation>DA:泰素 原研进口紫杉醇注射液，非凡品质，生命保证</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_1_4</masterLabel>
            <translation>Slides:紫杉醇的预处理</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1_3_1</masterLabel>
            <translation>泰素:达成目标</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_1_1</masterLabel>
            <translation>DA:泰素联合伯尔定作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_1_3</masterLabel>
            <translation>Slides:2013年NCCN指南解读</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_1_4</masterLabel>
            <translation>Slides:泰素联合伯尔定作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_2_1</masterLabel>
            <translation>DA:泰素联合伯尔定作为铂敏感型复发卵巢癌的首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2_2_5</masterLabel>
            <translation>Slides:泰素联合伯尔定作为铂敏感型复发卵巢癌的首选化疗方案</translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Material OTC --></label>
        <name>Material_OTC_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Ang_MT_1</masterLabel>
            <translation>Reprint：001试验、CV outcome</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ang_MT_2</masterLabel>
            <translation>DA: 安立泽-安心降糖，立刻选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ang_MT_3</masterLabel>
            <translation>Reprint：沙格列汀综述、001试验</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ang_MT_4</masterLabel>
            <translation>DT Slides：安心降糖，立刻选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BC_MT_1</masterLabel>
            <translation>BC 解热镇痛系列- 院内会slides (2009)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BC_MT_2</masterLabel>
            <translation>BC - DA 有效退热,安全可靠 (2008)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BC_MT_3</masterLabel>
            <translation>BC - 小礼品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_1</masterLabel>
            <translation>BP - DA 强效治头痛，一刻见轻松</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_2</masterLabel>
            <translation>BP - 样品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_3</masterLabel>
            <translation>BP - 小礼品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BP_MT_4</masterLabel>
            <translation>BP - 2011年院内会幻灯 - 全面迅速缓解各种头痛问题</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_1</masterLabel>
            <translation>Bco- 小礼品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_2</masterLabel>
            <translation>Bco- 维康福DA (国内配方最完整的复合维生素B)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_3</masterLabel>
            <translation>Bco - 样品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Bco_MT_4</masterLabel>
            <translation>Bco- 2009院内会幻灯</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_1</masterLabel>
            <translation>DA：双重保护、优势凸显</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_2</masterLabel>
            <translation>DA：什么是耐药基因屏障</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_3</masterLabel>
            <translation>DA：第一时间、第一选择</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_4</masterLabel>
            <translation>DA：长期治疗、物有所值</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_5</masterLabel>
            <translation>DA：病毒载量是肝脏损害加剧的独立危险因素</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_6</masterLabel>
            <translation>DA：经典品牌 无可替代</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DA_MT_7</masterLabel>
            <translation>DA：长期治疗、持续获益</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_1</masterLabel>
            <translation>DN - 小礼品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_2</masterLabel>
            <translation>DN- DA 2011(重视感冒早期症状，及时全面对症治疗)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_3</masterLabel>
            <translation>DN - 2011年院内会幻灯 - 以患者为中心，合理治疗感冒</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_4</masterLabel>
            <translation>DN-2011年院内会幻灯-重视感冒早期症状，及时全面对症治疗</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DN_MT_5</masterLabel>
            <translation>DN - 样品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_1</masterLabel>
            <translation>DA-艾乐妥抗凝1+1，客户观念深访</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_2</masterLabel>
            <translation>DA-艾乐妥助您的患者安度围术期</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis_MT_3</masterLabel>
            <translation>DA-阿哌沙班优化口服给药，优化抗凝</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_1</masterLabel>
            <translation>Leaflet：指南小卡片</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_2</masterLabel>
            <translation>Slides: 胰岛素联合格华止</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_3</masterLabel>
            <translation>Slides: 基础用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_4</masterLabel>
            <translation>Slides: 格华止的心血管保护</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_5</masterLabel>
            <translation>DA: 胰岛素联合格华止</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_6</masterLabel>
            <translation>Reprint: 口服降糖药物对2型糖尿病患者的疗效和安全性分析</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_7</masterLabel>
            <translation>DA: 2型糖尿病治疗的基础用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_8</masterLabel>
            <translation>DA: 心血管保护的循证医学证据</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glu_MT_9</masterLabel>
            <translation>DA: 合适剂量</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_1</masterLabel>
            <translation>DA: 蒙诺－高血压合并冠心病;慢性心力衰竭之基础用药</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_2</masterLabel>
            <translation>DA: 有蒙诺，FESTIVAL 常伴您</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monopril_MT_3</masterLabel>
            <translation>DA: 蒙诺－高血压合并卒中并伴发冠心病之基础用药(神内)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No Value</masterLabel>
            <translation><!-- No Value --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_1</masterLabel>
            <translation>DA:以伯尔定（卡铂）为基础的化疗方案--小细胞肺癌SCLC的标准一线化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_2</masterLabel>
            <translation>Slides:以伯尔定（卡铂）为基础的化疗方案--小细胞肺癌SCLC的标准一线化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_3</masterLabel>
            <translation>DA：原研进口卡铂注射液（伯尔定?）较顺铂更具优势的二代铂类药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_4</masterLabel>
            <translation>slides：原研进口卡铂注射液（伯尔定?）较顺铂更具优势的二代铂类药物</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_5</masterLabel>
            <translation>DA:泰素联合伯尔定作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_6</masterLabel>
            <translation>Slides:泰素联合伯尔定作为晚期卵巢癌首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_7</masterLabel>
            <translation>Slides:2013年NCCN指南解读</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_8</masterLabel>
            <translation>DA:泰素联合伯尔定作为铂敏感型复发卵巢癌的首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Paraplatin_MT_9</masterLabel>
            <translation>Slides:泰素联合伯尔定作为铂敏感型复发卵巢癌的首选化疗方案</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_1</masterLabel>
            <translation>TG - 2011院内会slides - 助益糖尿病健康</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_2</masterLabel>
            <translation>TG - 2011院内会slides - 慢病三级预防</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_3</masterLabel>
            <translation>TG - 小礼品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_4</masterLabel>
            <translation>TG - 样品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TG_MT_5</masterLabel>
            <translation>TG - 金施尔康DA（2009）</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TJD_MT_1</masterLabel>
            <translation>TJD - 小礼品</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TJD_MT_2</masterLabel>
            <translation>TJ - DA, 多种维生素与儿童常见疾病 (2009)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TJD_MT_3</masterLabel>
            <translation>TJD - 院内会slides (2008)</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_1</masterLabel>
            <translation>DA:泰素?  乳腺癌辅助治疗的“基石”</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_2</masterLabel>
            <translation>Slides:泰素? 乳腺癌辅助治疗的“基石”</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_3</masterLabel>
            <translation>DA:泰素 原研进口紫杉醇注射液，非凡品质，生命保证</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Taxol_MT_4</masterLabel>
            <translation>Slides:紫杉醇的预处理</translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Medical Communication Topic</label>
        <name>Med_Plan_Communication_Topic_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Medical Communication Topic --></label>
        <name>Medical_Communication_Topic_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>1st line Dasatanib Clinical Trials</masterLabel>
            <translation><!-- 1st line Dasatanib Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2013 Chinese CML treatment guideline</masterLabel>
            <translation><!-- 2013 Chinese CML treatment guideline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AMPLE Study</masterLabel>
            <translation><!-- AMPLE Study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AMPLIFY</masterLabel>
            <translation><!-- AMPLIFY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APPRAISE-2</masterLabel>
            <translation><!-- APPRAISE-2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARISTOTLE</masterLabel>
            <translation><!-- ARISTOTLE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ARISTOTLE &amp; AVERROES (including subgroup results)</masterLabel>
            <translation><!-- ARISTOTLE &amp; AVERROES (including subgroup results) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVERROES</masterLabel>
            <translation><!-- AVERROES --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Additional Benefits beyond glycemic control (weight loss, and reduction in SBP)</masterLabel>
            <translation><!-- Additional Benefits beyond glycemic control (weight loss, and reduction in SBP) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advancing LT Patient care and treatment interruption in patients with Stable CMR &quot;Funcitonal Cure&quot;</masterLabel>
            <translation><!-- Advancing LT Patient care and treatment interruption in patients with Stable CMR &quot;Funcitonal Cure&quot; --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advancing long-term patient care and treatment interruption in patients with stable CMR/”functional cure”</masterLabel>
            <translation><!-- Advancing long-term patient care and treatment interruption in patients with stable CMR/”functional cure” --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adverse Event Management</masterLabel>
            <translation><!-- Adverse Event Management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adverse event management in CML</masterLabel>
            <translation><!-- Adverse event management in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Amplify and Amplify EXT</masterLabel>
            <translation><!-- Amplify and Amplify EXT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban Timing of administration: 12-24 hrs post surgery fits in hospital pattern of care</masterLabel>
            <translation><!-- Apixaban Timing of administration: 12-24 hrs post surgery fits in hospital pattern of care --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixabans PK Profile with limited renal elimination</masterLabel>
            <translation><!-- Apixabans PK Profile with limited renal elimination --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS HCV Clinical Trials</masterLabel>
            <translation><!-- BMS HCV Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Burden of Atrial Fibrilation and Stroke in India</masterLabel>
            <translation><!-- Burden of Atrial Fibrilation and Stroke in India --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Burden of T2D, CV risk factors, complications and CV outcomes</masterLabel>
            <translation><!-- Burden of T2D, CV risk factors, complications and CV outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Burden of T2D: CV Risk factors, complicaitons and CV outcomes</masterLabel>
            <translation><!-- Burden of T2D: CV Risk factors, complicaitons and CV outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Catalyze changes in the treatment paradigm focusing on a Patient Centic approach</masterLabel>
            <translation><!-- Catalyze changes in the treatment paradigm focusing on a Patient Centic approach --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Efficacy and Safety of Dasatanib in CML</masterLabel>
            <translation><!-- Clinical Efficacy and Safety of Dasatanib in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Efficacy and Safety of Exenatide</masterLabel>
            <translation><!-- Clinical Efficacy and Safety of Exenatide --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Profile of Saxagliptin</masterLabel>
            <translation><!-- Clinical Profile of Saxagliptin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Co-morbidities in Atrial Fibrilation</masterLabel>
            <translation><!-- Co-morbidities in Atrial Fibrilation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate key data of SC Abatacept in RA management</masterLabel>
            <translation><!-- Communicate key data of SC Abatacept in RA management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate the commitment of AZ/BMS Alliance to Med Education and Clinical Research in T2D</masterLabel>
            <translation><!-- Communicate the commitment of AZ/BMS Alliance to Med Education and Clinical Research in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPA Monotherapy Trial Data</masterLabel>
            <translation><!-- DAPA Monotherapy Trial Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPA in Combination with Insulin</masterLabel>
            <translation><!-- DAPA in Combination with Insulin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPA in Combination with other oral glucose?lowering medicinal products Trial Data</masterLabel>
            <translation><!-- DAPA in Combination with other oral glucose?lowering medicinal products Trial Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss Abatacepts response kinetics, short term and LT efficacy, comparative efficacy to other biologics and safety (Clin trials and real-life)</masterLabel>
            <translation><!-- Discuss Abatacepts response kinetics, short term and LT efficacy, comparative efficacy to other biologics and safety (Clin trials and real-life) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss Baraclude long-term efficacy, resistance, safety in CHB na?ve patients and decompensated cirrhosis patients.</masterLabel>
            <translation><!-- Discuss Baraclude long-term efficacy, resistance, safety in CHB na?ve patients and decompensated cirrhosis patients. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss Baraclude value position and high pharmaceutical technology in CHB long-term patient management.</masterLabel>
            <translation><!-- Discuss Baraclude value position and high pharmaceutical technology in CHB long-term patient management. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss drug resistance and potential long-term impact on future treatment options and resistance management based on 2013 Chinese resistance consensus.</masterLabel>
            <translation><!-- Discuss drug resistance and potential long-term impact on future treatment options and resistance management based on 2013 Chinese resistance consensus. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss long term safety of NUC treatment, highlighting long-term safety of Nucleotide monotherapy and combination therapy.</masterLabel>
            <translation><!-- Discuss long term safety of NUC treatment, highlighting long-term safety of Nucleotide monotherapy and combination therapy. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the improvement of clinical outcomes during long-term antiviral treatment.</masterLabel>
            <translation><!-- Discuss the improvement of clinical outcomes during long-term antiviral treatment. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the updated knowledge in disease area and guidelines, highlighting the importance of treating na?ve patient with potent and high genetic barrier NUCs.</masterLabel>
            <translation><!-- Discuss the updated knowledge in disease area and guidelines, highlighting the importance of treating na?ve patient with potent and high genetic barrier NUCs. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss updated treatment guidelines (2012 ACR) highlighting the use of Abatacept as 1st line biologic and target of low disease activity/remission</masterLabel>
            <translation><!-- Discuss updated treatment guidelines (2012 ACR) highlighting the use of Abatacept as 1st line biologic and target of low disease activity/remission --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussing the unmet medical needs of Diabetes and its complications e.g. macrovascular complications</masterLabel>
            <translation><!-- Discussing the unmet medical needs of Diabetes and its complications e.g. macrovascular complications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discussion on AF treatment Guidelines</masterLabel>
            <translation><!-- Discussion on AF treatment Guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV EVOLVE Study</masterLabel>
            <translation><!-- ETV EVOLVE Study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV in CHB Patients undergoing chemo/immunosuppressive Therapy</masterLabel>
            <translation><!-- ETV in CHB Patients undergoing chemo/immunosuppressive Therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV in CHB Patients with HCC</masterLabel>
            <translation><!-- ETV in CHB Patients with HCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETV in CHB patients undergoing Liver Transplant</masterLabel>
            <translation><!-- ETV in CHB patients undergoing Liver Transplant --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCP on CHB disease, treatment guidelines and long term disease outcomes</masterLabel>
            <translation><!-- Educate HCP on CHB disease, treatment guidelines and long term disease outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCP on ETV in decompensated cirrhosis and OLT</masterLabel>
            <translation><!-- Educate HCP on ETV in decompensated cirrhosis and OLT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCP on ETV’s long-term efficacy, resistance profile, histological improvement and renal and bone safety from clinical trials and real-life data</masterLabel>
            <translation><!-- Educate HCP on ETV’s long-term efficacy, resistance profile, histological improvement and renal and bone safety from clinical trials and real-life data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and Safety of Abatacept in Lupus Nephritis</masterLabel>
            <translation><!-- Efficacy and Safety of Abatacept in Lupus Nephritis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy of Apixaban to prevent VTE/Death and major VTE vs enoxaparin 40 mg OD post THR/TKR Surgery</masterLabel>
            <translation><!-- Efficacy of Apixaban to prevent VTE/Death and major VTE vs enoxaparin 40 mg OD post THR/TKR Surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy- Significant reduction of total VTE/Death and Major VTEs when compared to Enoxaparin 40 mg OD</masterLabel>
            <translation><!-- Efficacy- Significant reduction of total VTE/Death and Major VTEs when compared to Enoxaparin 40 mg OD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establishing saxagliptin’s efficacy in add-on to metformin through comprehensive control of HbA1c, FPG, PPG, as well as safety and long term durability</masterLabel>
            <translation><!-- Establishing saxagliptin’s efficacy in add-on to metformin through comprehensive control of HbA1c, FPG, PPG, as well as safety and long term durability --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Exanetides place in the treatment arnament for T2D</masterLabel>
            <translation><!-- Exanetides place in the treatment arnament for T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Exenatide and Add-onto-Insulin; Add-onto-TZD</masterLabel>
            <translation><!-- Exenatide and Add-onto-Insulin; Add-onto-TZD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Exenatide and TZD or Insulin add on studies</masterLabel>
            <translation><!-- Exenatide and TZD or Insulin add on studies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Holistic apporach and benefits of multi-factorial intervention in T2D</masterLabel>
            <translation><!-- Holistic apporach and benefits of multi-factorial intervention in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Holistic approach and benefits of multifactorial intervention in T2D</masterLabel>
            <translation><!-- Holistic approach and benefits of multifactorial intervention in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of early time to response and depth of response on LT patient outcomes</masterLabel>
            <translation><!-- Impact of early time to response and depth of response on LT patient outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of early time to response and depth of response on long term patient outcomes (the benefit of “early switch”)</masterLabel>
            <translation><!-- Impact of early time to response and depth of response on long term patient outcomes (the benefit of “early switch”) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of CV Disease Prevention in T2D</masterLabel>
            <translation><!-- Importance of CV Disease Prevention in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of a Patient Centric approach in T2D treatment</masterLabel>
            <translation><!-- Importance of a Patient Centric approach in T2D treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of adherence in CML</masterLabel>
            <translation><!-- Importance of adherence in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Key Players in glucose balance including the role of the kidney</masterLabel>
            <translation><!-- Key Players in glucose balance including the role of the kidney --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of Current Therapies</masterLabel>
            <translation><!-- Limitations of Current Therapies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of current insulin-dependent therapies. Progressive beta-cell failure and treatment failures</masterLabel>
            <translation><!-- Limitations of current insulin-dependent therapies. Progressive beta-cell failure and treatment failures --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of current insulin-dependent therapies: Progressive beta cell failure and treatment failure</masterLabel>
            <translation><!-- Limitations of current insulin-dependent therapies: Progressive beta cell failure and treatment failure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limited renal elimitation compared to other NOACs</masterLabel>
            <translation><!-- Limited renal elimitation compared to other NOACs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-Term Patient Management strategies for GI side effects</masterLabel>
            <translation><!-- Long-Term Patient Management strategies for GI side effects --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term Impact of Exenatide on Beta cell function</masterLabel>
            <translation><!-- Long-term Impact of Exenatide on Beta cell function --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MOA of DAPA</masterLabel>
            <translation><!-- MOA of DAPA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MoA of SGLT2 inibitor: Global 066 renal splay</masterLabel>
            <translation><!-- MoA of SGLT2 inibitor: Global 066 renal splay --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Monotherapy: Global 013/ China 054</masterLabel>
            <translation><!-- Monotherapy: Global 013/ China 054 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option1</masterLabel>
            <translation><!-- Option1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option2</masterLabel>
            <translation><!-- Option2 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option3</masterLabel>
            <translation><!-- Option3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option4</masterLabel>
            <translation><!-- Option4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Option5</masterLabel>
            <translation><!-- Option5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other</masterLabel>
            <translation><!-- Other --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other CV Clinical Trials</masterLabel>
            <translation><!-- Other CV Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Dasatanib Clinical Trials</masterLabel>
            <translation><!-- Other Dasatanib Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Metabolic Clinical Trials</masterLabel>
            <translation><!-- Other Metabolic Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Oncology Clinical Trials</masterLabel>
            <translation><!-- Other Oncology Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Other Virology Clinical Trials</masterLabel>
            <translation><!-- Other Virology Clinical Trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ph+ALL treatment and Key Dasatanib trial data</masterLabel>
            <translation><!-- Ph+ALL treatment and Key Dasatanib trial data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ph+ALL treatmenta and Key Dasatanib trial data</masterLabel>
            <translation><!-- Ph+ALL treatmenta and Key Dasatanib trial data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Potential CV Protective role of Incretin based treatments</masterLabel>
            <translation><!-- Potential CV Protective role of Incretin based treatments --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Potential CV Protective role of Incretin class</masterLabel>
            <translation><!-- Potential CV Protective role of Incretin class --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use of Apixaban in VTEP management</masterLabel>
            <translation><!-- Practical use of Apixaban in VTEP management --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Rationale for BID Dosing: Apixabans PK profile and Phase 2 study results</masterLabel>
            <translation><!-- Rationale for BID Dosing: Apixabans PK profile and Phase 2 study results --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Relative merits of glycaemic control</masterLabel>
            <translation><!-- Relative merits of glycaemic control --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPAF Disease Burden, the limitations of current therapies, Co-morbidities in AF,  &amp; economic impact of AF)</masterLabel>
            <translation><!-- SPAF Disease Burden, the limitations of current therapies, Co-morbidities in AF,  &amp; economic impact of AF) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety Retrospective CV Safety Data</masterLabel>
            <translation><!-- Safety Retrospective CV Safety Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety of Apixaban in Post THR/TKR Surgery</masterLabel>
            <translation><!-- Safety of Apixaban in Post THR/TKR Surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety, including renal safety, infections and cancer</masterLabel>
            <translation><!-- Safety, including renal safety, infections and cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety, including renal safety, infections and cancer: Pooled analysis</masterLabel>
            <translation><!-- Safety, including renal safety, infections and cancer: Pooled analysis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety- No increase in major or CRNM bleeds</masterLabel>
            <translation><!-- Safety- No increase in major or CRNM bleeds --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety: retrospective CV Safety data</masterLabel>
            <translation><!-- Safety: retrospective CV Safety data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin China Add-On Clinical Trials: Combination with Met, FDC, and add-onto-Insulin</masterLabel>
            <translation><!-- Saxagliptin China Add-On Clinical Trials: Combination with Met, FDC, and add-onto-Insulin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin Efficacy as either Monotherapy or in initial combination with Metformin</masterLabel>
            <translation><!-- Saxagliptin Efficacy as either Monotherapy or in initial combination with Metformin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin Global Add-On Clinical trials: SU, Insulin, TZDS</masterLabel>
            <translation><!-- Saxagliptin Global Add-On Clinical trials: SU, Insulin, TZDS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Saxagliptin as add-onto Insulin (057 study) or Saxagliptin Triple Therapy Study</masterLabel>
            <translation><!-- Saxagliptin as add-onto Insulin (057 study) or Saxagliptin Triple Therapy Study --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>The clinical efficacy and safety of Dasatinib in 2nd line of CML (034 data and local 160 data)</masterLabel>
            <translation><!-- The clinical efficacy and safety of Dasatinib in 2nd line of CML (034 data and local 160 data) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Timing of Apixaban administration after Surgery</masterLabel>
            <translation><!-- Timing of Apixaban administration after Surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet Medical needs in T2D</masterLabel>
            <translation><!-- Unmet Medical needs in T2D --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet medical needs in T2D: Limitations of current treatment options including weight gain, hypoglycemia, CV Safety concerns.</masterLabel>
            <translation><!-- Unmet medical needs in T2D: Limitations of current treatment options including weight gain, hypoglycemia, CV Safety concerns. --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VTEP Disease Burden &amp; its undertreatment in China</masterLabel>
            <translation><!-- VTEP Disease Burden &amp; its undertreatment in China --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Medical Communication Topic --></label>
        <name>Medical_Communication_Topic_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>AEs: Support medical education to ensure safe and appropriate use of Nivolumab monotherapy</masterLabel>
            <translation><!-- AEs: Support medical education to ensure safe and appropriate use of Nivolumab monotherapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Accelerate the understanding &amp; value of immuno-oncology in the treatment of  NSCLC and melanoma</masterLabel>
            <translation><!-- Accelerate the understanding &amp; value of immuno-oncology in the treatment of  NSCLC and melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Address suboptimal anticoagulation - Discuss limitations of VKA in relation to Apixaban</masterLabel>
            <translation><!-- Address suboptimal anticoagulation - Discuss limitations of VKA in relation to Apixaban --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Address undiagnosed/ untreated patients  and  discuss the health economic rationale of AF screening in high-risk patients</masterLabel>
            <translation><!-- Address undiagnosed/ untreated patients  and  discuss the health economic rationale of AF screening in high-risk patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Advancing long-term patient care and treatment interruption in patients with stable CMR/&quot;functional cure&quot;</masterLabel>
            <translation><!-- Advancing long-term patient care and treatment interruption in patients with stable CMR/&quot;functional cure&quot; --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Adverse events/Safety: Facilitate appropriate understanding of AE’s management with established guidelines and existing algorithm</masterLabel>
            <translation><!-- Adverse events/Safety: Facilitate appropriate understanding of AE’s management with established guidelines and existing algorithm --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Amplify / VTE treatment</masterLabel>
            <translation><!-- Amplify / VTE treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Answer questions on  bleeding /reversal data and timelines of availability</masterLabel>
            <translation><!-- Answer questions on  bleeding /reversal data and timelines of availability --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Apixaban pharmacokinetic and pharmacodynamic properties</masterLabel>
            <translation><!-- Apixaban pharmacokinetic and pharmacodynamic properties --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate communication on the clinical value of elotuzumab</masterLabel>
            <translation><!-- Appropriate communication on the clinical value of elotuzumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate communication on the clinical value of elotuzumab (reactive)</masterLabel>
            <translation><!-- Appropriate communication on the clinical value of elotuzumab (reactive) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate communication on the economic and societal value of immuno-oncology</masterLabel>
            <translation><!-- Appropriate communication on the economic and societal value of immuno-oncology --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on SLAMF7 as a critical target in MM</masterLabel>
            <translation><!-- Appropriate education on SLAMF7 as a critical target in MM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on SLAMF7 as an I-O target in MM and establish the role of I-O in MM</masterLabel>
            <translation><!-- Appropriate education on SLAMF7 as an I-O target in MM and establish the role of I-O in MM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on the clinical data and the relevant place of therapy for Elotuzumab in RRMM</masterLabel>
            <translation><!-- Appropriate education on the clinical data and the relevant place of therapy for Elotuzumab in RRMM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriate education on the rationale and clinical value of further studying immuno-oncology in melanoma</masterLabel>
            <translation><!-- Appropriate education on the rationale and clinical value of further studying immuno-oncology in melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately communicate on the clinical data for nivolumab in Hodgkin lymphoma</masterLabel>
            <translation><!-- Appropriately communicate on the clinical data for nivolumab in Hodgkin lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately communicate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA in eRP RA patients</masterLabel>
            <translation><!-- Appropriately communicate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA in eRP RA patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately communicate time out of refrigeration data for Orencia</masterLabel>
            <translation><!-- Appropriately communicate time out of refrigeration data for Orencia --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately discuss BMS commitment to rheumatology and immunoscience by highlighting the Orencia LCM program and the BMS immunoscience pipeline</masterLabel>
            <translation><!-- Appropriately discuss BMS commitment to rheumatology and immunoscience by highlighting the Orencia LCM program and the BMS immunoscience pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately educate on rationale for I-O therapies in HL</masterLabel>
            <translation><!-- Appropriately educate on rationale for I-O therapies in HL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Appropriately initiate or switch to aripiprazole in BD &amp; SCZ and acute and long term efficacy and tolerability of aripiprazole in adult and adolescent SCZ patients</masterLabel>
            <translation><!-- Appropriately initiate or switch to aripiprazole in BD &amp; SCZ and acute and long term efficacy and tolerability of aripiprazole in adult and adolescent SCZ patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Aripiprazole from the start of a mania episode in adult BD and maintaining treatment in the long term in monotherapy or in combination with a mood stabilizer</masterLabel>
            <translation><!-- Aripiprazole from the start of a mania episode in adult BD and maintaining treatment in the long term in monotherapy or in combination with a mood stabilizer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Aristotle sub-analysis</masterLabel>
            <translation><!-- Aristotle sub-analysis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Averroes sub-analysis</masterLabel>
            <translation><!-- Averroes sub-analysis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BID dosing</masterLabel>
            <translation><!-- BID dosing --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS/AZ diabetes product range</masterLabel>
            <translation><!-- BMS/AZ diabetes product range --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Based on clinical profile, apixaban is cost-effective vs all anti-coagulants (including costs per stroke/bleeds, QALYs, and QoL inputs)</masterLabel>
            <translation><!-- Based on clinical profile, apixaban is cost-effective vs all anti-coagulants (including costs per stroke/bleeds, QALYs, and QoL inputs) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Belatacept is the first-in-class selective co-stimulation blocker that prevents T-cell activation</masterLabel>
            <translation><!-- Belatacept is the first-in-class selective co-stimulation blocker that prevents T-cell activation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Belatacept profile on Application, PK/PD and TDM</masterLabel>
            <translation><!-- Belatacept profile on Application, PK/PD and TDM --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Belatacept results in high patients and graft survival in kidney transplant recipients in relation to long term safety</masterLabel>
            <translation><!-- Belatacept results in high patients and graft survival in kidney transplant recipients in relation to long term safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Blood pressure effect</masterLabel>
            <translation><!-- Blood pressure effect --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CV research- Discussion of potential apixaban clinical research beyond NVAF &amp; VTEtx</masterLabel>
            <translation><!-- CV research- Discussion of potential apixaban clinical research beyond NVAF &amp; VTEtx --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cardiovascular safety of Saxagliptin (SAVOR data)</masterLabel>
            <translation><!-- Cardiovascular safety of Saxagliptin (SAVOR data) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clarify Guidelines strongly limited usage of aspirin in SPAF, supported by data proven its limited benefits and share new option availability supported by direct comparison versus aspirin (AVERROES)</masterLabel>
            <translation><!-- Clarify Guidelines strongly limited usage of aspirin in SPAF, supported by data proven its limited benefits and share new option availability supported by direct comparison versus aspirin (AVERROES) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clarify VKA Limitations</masterLabel>
            <translation><!-- Clarify VKA Limitations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clarify how Apixaban ongoing life cycle program is addressing critical unmet needs in AF and VTE, identify data gap and contribute to address clinical unmet  medical needs</masterLabel>
            <translation><!-- Clarify how Apixaban ongoing life cycle program is addressing critical unmet needs in AF and VTE, identify data gap and contribute to address clinical unmet  medical needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trials - Discuss planned or ongoing company sponsored studies</masterLabel>
            <translation><!-- Clinical Trials - Discuss planned or ongoing company sponsored studies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical Trials - Discuss potential or ongoing “on Strategy”  ISRs</masterLabel>
            <translation><!-- Clinical Trials - Discuss potential or ongoing “on Strategy”  ISRs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical profile of exenatide once weekly (QW)</masterLabel>
            <translation><!-- Clinical profile of exenatide once weekly (QW) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical profile of exenatide twice daily (BID)</masterLabel>
            <translation><!-- Clinical profile of exenatide twice daily (BID) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Clinical profile of saxagliptin</masterLabel>
            <translation><!-- Clinical profile of saxagliptin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Combination Regimen: Communicate appropriately on Combination regimen data and BMS clinical trials program to answer unmet medical needs</masterLabel>
            <translation><!-- Combination Regimen: Communicate appropriately on Combination regimen data and BMS clinical trials program to answer unmet medical needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Combination Regimen: Support medical exchange on Nivolumab plus Ipilimumab Combination Regimen patient benefit</masterLabel>
            <translation><!-- Combination Regimen: Support medical exchange on Nivolumab plus Ipilimumab Combination Regimen patient benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate Apixaban medical value story based on TLs needs</masterLabel>
            <translation><!-- Communicate Apixaban medical value story based on TLs needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate Efficacy, safety and Tolerability of EFV regimens in naïve with focus on comparison of EFV vs. Rilpivirine in terms of viral failure and emergence of cross resistance</masterLabel>
            <translation><!-- Communicate Efficacy, safety and Tolerability of EFV regimens in naïve with focus on comparison of EFV vs. Rilpivirine in terms of viral failure and emergence of cross resistance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate appropriate dosing, efficacy and safety of ATV powder in children</masterLabel>
            <translation><!-- Communicate appropriate dosing, efficacy and safety of ATV powder in children --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate clinical and RW data that identify complementary eRP patient characteristics and validate the incremental efficacy of abatacept in select other patient types</masterLabel>
            <translation><!-- Communicate clinical and RW data that identify complementary eRP patient characteristics and validate the incremental efficacy of abatacept in select other patient types --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate data from ALLY-1 showing the efficacy and safety of DCV combined with SOF in the peri-transplant setting</masterLabel>
            <translation><!-- Communicate data from ALLY-1 showing the efficacy and safety of DCV combined with SOF in the peri-transplant setting --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate role of PI-based tx for durable suppression w low rates of resistance</masterLabel>
            <translation><!-- Communicate role of PI-based tx for durable suppression w low rates of resistance --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate that DCV has been studied in various combinations with NS3, NS5B  inhibitors and pegIFN+RBV in Phase 1, 2, and 3 studies in GT-1, -4 patients with high unmet needs</masterLabel>
            <translation><!-- Communicate that DCV has been studied in various combinations with NS3, NS5B  inhibitors and pegIFN+RBV in Phase 1, 2, and 3 studies in GT-1, -4 patients with high unmet needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate that DCV is a potent new NS5A replication complex inhibitor with a pan-genotypic profile against the hepatitis C virus</masterLabel>
            <translation><!-- Communicate that DCV is a potent new NS5A replication complex inhibitor with a pan-genotypic profile against the hepatitis C virus --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate the value of Orencia’s formulation versatility via the autoinjector (AI) launch and availability of pediatric SC data sets</masterLabel>
            <translation><!-- Communicate the value of Orencia’s formulation versatility via the autoinjector (AI) launch and availability of pediatric SC data sets --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Communicate through scientific exchange on efficacy and safety data for nivolumab as a treatment option for mRCC therapy</masterLabel>
            <translation><!-- Communicate through scientific exchange on efficacy and safety data for nivolumab as a treatment option for mRCC therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Core Orencia Messages and Clinical Data: MOA, Onset of action, ST &amp; LT Efficacy, breaking aTNF cycling,structural demage (XR, MRI, PDUS results), safety</masterLabel>
            <translation><!-- Core Orencia Messages and Clinical Data: MOA, Onset of action, ST &amp; LT Efficacy, breaking aTNF cycling,structural demage (XR, MRI, PDUS results), safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Core component of CML therapy</masterLabel>
            <translation><!-- Core component of CML therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Dasatinib provides value to patients by effectively targeting the disease, reducing risk of early progression, providing early deep responses and a predictable less bothersome tolerability profile with long term follow-up</masterLabel>
            <translation><!-- Dasatinib provides value to patients by effectively targeting the disease, reducing risk of early progression, providing early deep responses and a predictable less bothersome tolerability profile with long term follow-up --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Demonstrate  why ASA use is inappropriate</masterLabel>
            <translation><!-- Demonstrate  why ASA use is inappropriate --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Demonstrate BMS&apos; commitment to rheumatology and immunoscience by highlighting the LCM and pipeline</masterLabel>
            <translation><!-- Demonstrate BMS&apos; commitment to rheumatology and immunoscience by highlighting the LCM and pipeline --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Differentiate  Apixaban from the other oral anticoagulants</masterLabel>
            <translation><!-- Differentiate  Apixaban from the other oral anticoagulants --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Differentiate ATV vs DRV based on PK &amp; durable suppression in many ARV strategies</masterLabel>
            <translation><!-- Differentiate ATV vs DRV based on PK &amp; durable suppression in many ARV strategies --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Differentiate Apixaban vs other OACs</masterLabel>
            <translation><!-- Differentiate Apixaban vs other OACs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss CA209-026 lung data presented at ESMO 2016</masterLabel>
            <translation><!-- Discuss CA209-026 lung data presented at ESMO 2016 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss areas of unmet medical need in Lupus Nephritis</masterLabel>
            <translation><!-- Discuss areas of unmet medical need in Lupus Nephritis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss data from studies 040 and ALLY-3 showing the efficacy and safety of DCV combined with SOF in genotype 3 patients</masterLabel>
            <translation><!-- Discuss data from studies 040 and ALLY-3 showing the efficacy and safety of DCV combined with SOF in genotype 3 patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss evidence which supports positioning of Apixaban on Clinical Guidelines</masterLabel>
            <translation><!-- Discuss evidence which supports positioning of Apixaban on Clinical Guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss resistance profile of DCV</masterLabel>
            <translation><!-- Discuss resistance profile of DCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the burden of HCV infection</masterLabel>
            <translation><!-- Discuss the burden of HCV infection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Discuss the challenges around HIV/HCV co-infection</masterLabel>
            <translation><!-- Discuss the challenges around HIV/HCV co-infection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disease awareness</masterLabel>
            <translation><!-- Disease awareness --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EHRA guidelines</masterLabel>
            <translation><!-- EHRA guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ESC guidelines</masterLabel>
            <translation><!-- ESC guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EULAR and treat to target recommendations</masterLabel>
            <translation><!-- EULAR and treat to target recommendations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early deep response to therapy is associated with longer progression free and overall survival</masterLabel>
            <translation><!-- Early deep response to therapy is associated with longer progression free and overall survival --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCPs on the appropriate use of Nivolumab in the treatment of lung cancer</masterLabel>
            <translation><!-- Educate HCPs on the appropriate use of Nivolumab in the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate HCPs on the safety profile and appropriate use of Nivolumab in the treatment of lung cancer</masterLabel>
            <translation><!-- Educate HCPs on the safety profile and appropriate use of Nivolumab in the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate around the particular burden of HCV Genotype 3 infection</masterLabel>
            <translation><!-- Educate around the particular burden of HCV Genotype 3 infection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate market access stakeholders and specialty pharmacies on the value of DCV+SOF</masterLabel>
            <translation><!-- Educate market access stakeholders and specialty pharmacies on the value of DCV+SOF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on GT-3 HCV disease state</masterLabel>
            <translation><!-- Educate on GT-3 HCV disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on HIV/HCV coinfection  disease state</masterLabel>
            <translation><!-- Educate on HIV/HCV coinfection  disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on advanced cirrhosis HCV disease state</masterLabel>
            <translation><!-- Educate on advanced cirrhosis HCV disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on post liver transplant HCV disease state</masterLabel>
            <translation><!-- Educate on post liver transplant HCV disease state --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the DDI profile of DCV</masterLabel>
            <translation><!-- Educate on the DDI profile of DCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the appropriate dosing and safety profile of DCV</masterLabel>
            <translation><!-- Educate on the appropriate dosing and safety profile of DCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the efficacy and safety of DCV+SOF in GT-3 patients</masterLabel>
            <translation><!-- Educate on the efficacy and safety of DCV+SOF in GT-3 patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the efficacy and safety of DCV+SOF+RBV in GT-3 patients with compensated cirrhosis</masterLabel>
            <translation><!-- Educate on the efficacy and safety of DCV+SOF+RBV in GT-3 patients with compensated cirrhosis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the rationale and potential of immuno-oncology in cancer</masterLabel>
            <translation><!-- Educate on the rationale and potential of immuno-oncology in cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the rationale and value of research of immuno-oncology (I-O) agents as a treatment option in NSCLC and potentially also for SCLC</masterLabel>
            <translation><!-- Educate on the rationale and value of research of immuno-oncology (I-O) agents as a treatment option in NSCLC and potentially also for SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the rationale and value of studying immuno-oncology (I-O) in lung cancer</masterLabel>
            <translation><!-- Educate on the rationale and value of studying immuno-oncology (I-O) in lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the role of PD-L1 as a potential biomarker for NSCLC</masterLabel>
            <translation><!-- Educate on the role of PD-L1 as a potential biomarker for NSCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the unmet medical need and guidelines on treatment of NSCLC and melanoma</masterLabel>
            <translation><!-- Educate on the unmet medical need and guidelines on treatment of NSCLC and melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate on the value to HCPs / patients / payers</masterLabel>
            <translation><!-- Educate on the value to HCPs / patients / payers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Educate payor groups &amp; clinical market access stakeholders on ATV value</masterLabel>
            <translation><!-- Educate payor groups &amp; clinical market access stakeholders on ATV value --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Effects of exenatide on gastric emptying and central appetite control (BID)</masterLabel>
            <translation><!-- Effects of exenatide on gastric emptying and central appetite control (BID) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of DCV+SOF in HIV/HCV coinfection</masterLabel>
            <translation><!-- Efficacy and safety of DCV+SOF in HIV/HCV coinfection --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of DCV+SOF+RBV in advanced cirrhosis</masterLabel>
            <translation><!-- Efficacy and safety of DCV+SOF+RBV in advanced cirrhosis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of DCV+SOF+RBV post liver transplant</masterLabel>
            <translation><!-- Efficacy and safety of DCV+SOF+RBV post liver transplant --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy and safety of aripiprazole in the relevant patients</masterLabel>
            <translation><!-- Efficacy and safety of aripiprazole in the relevant patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy of apixaban to prevent VTE/death and major VTE vs enoxaparin 40 mg OD in THR and TKR surgery</masterLabel>
            <translation><!-- Efficacy of apixaban to prevent VTE/death and major VTE vs enoxaparin 40 mg OD in THR and TKR surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Efficacy/safety profile: Apixaban demonstrated efficacy benefit, safety benefit and mortality benefit across a wide range of patients</masterLabel>
            <translation><!-- Efficacy/safety profile: Apixaban demonstrated efficacy benefit, safety benefit and mortality benefit across a wide range of patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Enhance awareness of abatacept’s safety profile</masterLabel>
            <translation><!-- Enhance awareness of abatacept’s safety profile --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Enhance the understanding &amp; value of immuno-oncology in the treatment of lung cancer</masterLabel>
            <translation><!-- Enhance the understanding &amp; value of immuno-oncology in the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Enhance understanding of I-O in the treatment of metastatic melanoma</masterLabel>
            <translation><!-- Enhance understanding of I-O in the treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ensure payers /hospital awareness on apixaban value and appropriate use</masterLabel>
            <translation><!-- Ensure payers /hospital awareness on apixaban value and appropriate use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establish abatacept’s ability to achieve robust remission rates in early RA patients with potential to de-escalate or withdraw therapy</masterLabel>
            <translation><!-- Establish abatacept’s ability to achieve robust remission rates in early RA patients with potential to de-escalate or withdraw therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establish the benefits of abatacept as an optimal choice for patients with early, rapidly progressing rheumatoid arthritis</masterLabel>
            <translation><!-- Establish the benefits of abatacept as an optimal choice for patients with early, rapidly progressing rheumatoid arthritis --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Establish the benefits of first-line use of abatacept in biologic naïve and 1st -switch RA patients versus TNFi, TNF cycling and other biologic agents</masterLabel>
            <translation><!-- Establish the benefits of first-line use of abatacept in biologic naïve and 1st -switch RA patients versus TNFi, TNF cycling and other biologic agents --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Existing and future treatment guidelines in BD and data relevant to guideline development</masterLabel>
            <translation><!-- Existing and future treatment guidelines in BD and data relevant to guideline development --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Explain DCV’s safety and tolerability profile, with QD dosing, and a favorable DDI profile, making it an important component of therapeutic regimens for patients with high unmet needs</masterLabel>
            <translation><!-- Explain DCV’s safety and tolerability profile, with QD dosing, and a favorable DDI profile, making it an important component of therapeutic regimens for patients with high unmet needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Explain how Apixaban RWD / HEOR complements the safety and efficacy demonstrated in  randomised controlled trials</masterLabel>
            <translation><!-- Explain how Apixaban RWD / HEOR complements the safety and efficacy demonstrated in  randomised controlled trials --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Favorable recommendations for DPPIV inhibitors vs SUs in the 2012 ADA/EASD position statement</masterLabel>
            <translation><!-- Favorable recommendations for DPPIV inhibitors vs SUs in the 2012 ADA/EASD position statement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Favorable recommendations for GLP-1 agonists in the ADA/EASD position statement</masterLabel>
            <translation><!-- Favorable recommendations for GLP-1 agonists in the ADA/EASD position statement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GU experience and knowledge: Leverage existing Nivolumab experience in RCC and BMS leadership in I-O in other indications</masterLabel>
            <translation><!-- GU experience and knowledge: Leverage existing Nivolumab experience in RCC and BMS leadership in I-O in other indications --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glycemic efficacy</masterLabel>
            <translation><!-- Glycemic efficacy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>H2H and AMPLE 1 and 2 y results</masterLabel>
            <translation><!-- H2H and AMPLE 1 and 2 y results --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Genotype Impact &amp; specific patient populations</masterLabel>
            <translation><!-- HCV Genotype Impact &amp; specific patient populations --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEOR/Sustained value to patients and HCPs</masterLabel>
            <translation><!-- HEOR/Sustained value to patients and HCPs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs</masterLabel>
            <translation><!-- Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs in focused patient type, linking clinical outcomes to underlying pathology and MoA of abatacept</masterLabel>
            <translation><!-- Highlight current areas of unmet medical need in PsA and discuss how abatacept may address certain of these needs in focused patient type, linking clinical outcomes to underlying pathology and MoA of abatacept --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Highlight patient profiles that are particularly likely to benefit from abatacept therapy</masterLabel>
            <translation><!-- Highlight patient profiles that are particularly likely to benefit from abatacept therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO Medical education: Support better understanding of I-O therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option</masterLabel>
            <translation><!-- IO Medical education: Support better understanding of I-O therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO concept: Educate HCP on the rationale for studying the Potential of Immuno-Oncology in Genitourinary Cancers</masterLabel>
            <translation><!-- IO concept: Educate HCP on the rationale for studying the Potential of Immuno-Oncology in Genitourinary Cancers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO for mRCC: Inform TL on evolving advances in treatment and communicate the clinical value of IO in mRCC</masterLabel>
            <translation><!-- IO for mRCC: Inform TL on evolving advances in treatment and communicate the clinical value of IO in mRCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IO medical education: Support better understanding of IO therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option</masterLabel>
            <translation><!-- IO medical education: Support better understanding of IO therapy rational and benefits as well as early identification and management of irAEs to ensure safe and appropriate use of these important new treatment option --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Impact of early time to response  and depth of response on long term patient outcomes</masterLabel>
            <translation><!-- Impact of early time to response  and depth of response on long term patient outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of Cardiovascular Disease in type 2 diabetes and a multidisciplinary management approach</masterLabel>
            <translation><!-- Importance of Cardiovascular Disease in type 2 diabetes and a multidisciplinary management approach --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of adherence in CML</masterLabel>
            <translation><!-- Importance of adherence in CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of continuing on therapy (adherence)</masterLabel>
            <translation><!-- Importance of continuing on therapy (adherence) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of patient preference and adherence in type 2 diabetes management (QW)</masterLabel>
            <translation><!-- Importance of patient preference and adherence in type 2 diabetes management (QW) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of patient-centric approach in diabetes treatment</masterLabel>
            <translation><!-- Importance of patient-centric approach in diabetes treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Importance of response to first line therapy</masterLabel>
            <translation><!-- Importance of response to first line therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Indication</masterLabel>
            <translation><!-- Indication --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on guidelines on the treatment of lung cancer</masterLabel>
            <translation><!-- Inform on guidelines on the treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the on-going unmet medical needs in lung cancer</masterLabel>
            <translation><!-- Inform on the on-going unmet medical needs in lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need and guidelines on treatment of lung cancer</masterLabel>
            <translation><!-- Inform on the unmet medical need and guidelines on treatment of lung cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need and guidelines on treatment of metastatic melanoma</masterLabel>
            <translation><!-- Inform on the unmet medical need and guidelines on treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need despite recent and evolving advances in treatment</masterLabel>
            <translation><!-- Inform on the unmet medical need despite recent and evolving advances in treatment --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need in the treatment of Hodgkin Lymphoma</masterLabel>
            <translation><!-- Inform on the unmet medical need in the treatment of Hodgkin Lymphoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Inform on the unmet medical need in the treatment of multiple myeloma</masterLabel>
            <translation><!-- Inform on the unmet medical need in the treatment of multiple myeloma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ipi mono: Share durable, long-term survival benefit in pts with adv. Mel. and antitumor activity across pt subgroups. Ipi is associated with immune-mediated adverse reactions, but most were reversible in studies using established mgmt guidelines</masterLabel>
            <translation><!-- Ipi mono: Share durable, long-term survival benefit in pts with adv. Mel. and antitumor activity across pt subgroups. Ipi is associated with immune-mediated adverse reactions, but most were reversible in studies using established mgmt guidelines --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LCM: Disseminate key scientific, clinical, and outcome–related data from the LCM space to enable a greater understanding of I-O for the advancement of scientific knowledge</masterLabel>
            <translation><!-- LCM: Disseminate key scientific, clinical, and outcome–related data from the LCM space to enable a greater understanding of I-O for the advancement of scientific knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Limitations of currently available immunosuppressive therapies, protocols and their impact on renal function, graft and Patient survival, acute rejection and the relationship of safety and LT outcome</masterLabel>
            <translation><!-- Limitations of currently available immunosuppressive therapies, protocols and their impact on renal function, graft and Patient survival, acute rejection and the relationship of safety and LT outcome --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term Patient Outcomes</masterLabel>
            <translation><!-- Long-term Patient Outcomes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term Potency</masterLabel>
            <translation><!-- Long-term Potency --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Long-term safety</masterLabel>
            <translation><!-- Long-term safety --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MOA</masterLabel>
            <translation><!-- MOA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Medical Value message (HEOR): Orencia in real life, ACTION, ASCORE,local registries</masterLabel>
            <translation><!-- Medical Value message (HEOR): Orencia in real life, ACTION, ASCORE,local registries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Misc - answer questions on MOA, DDI or general practical use  / disease or NOAC overview education</masterLabel>
            <translation><!-- Misc - answer questions on MOA, DDI or general practical use  / disease or NOAC overview education --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5A-inhibition</masterLabel>
            <translation><!-- NS5A-inhibition --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivo mono: Appropriately communicate data on OS benefit and durable response, across lines of therapies, melanoma tumor status, PDL-1 expression</masterLabel>
            <translation><!-- Nivo mono: Appropriately communicate data on OS benefit and durable response, across lines of therapies, melanoma tumor status, PDL-1 expression --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab 2nd line (025): Communicate the clinical value and patient benefit and safety profile of nivolumab</masterLabel>
            <translation><!-- Nivolumab 2nd line (025): Communicate the clinical value and patient benefit and safety profile of nivolumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab Mono in 2L: Communicate appropriately on data on OS, long term OS, ORR and quality of life benefit</masterLabel>
            <translation><!-- Nivolumab Mono in 2L: Communicate appropriately on data on OS, long term OS, ORR and quality of life benefit --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Nivolumab Mono in 2L: Raise awareness of current unmet medical need across the bladder cancer treatment continuum and appropriately communicate Nivolumab clinical trial program and existing data</masterLabel>
            <translation><!-- Nivolumab Mono in 2L: Raise awareness of current unmet medical need across the bladder cancer treatment continuum and appropriately communicate Nivolumab clinical trial program and existing data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Ongoing Clinical Trials – LCM - Discuss planned or ongoing ACROPOLIS studies including Alliance sponsored, ISR research and  RISTA  programme. excluding study support</masterLabel>
            <translation><!-- Ongoing Clinical Trials – LCM - Discuss planned or ongoing ACROPOLIS studies including Alliance sponsored, ISR research and  RISTA  programme. excluding study support --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PK profile with limited renal elimination</masterLabel>
            <translation><!-- PK profile with limited renal elimination --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Potential effect of HBR on chronic inflammation and CV risk</masterLabel>
            <translation><!-- Potential effect of HBR on chronic inflammation and CV risk --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use</masterLabel>
            <translation><!-- Practical use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use of Apixaban</masterLabel>
            <translation><!-- Practical use of Apixaban --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Practical use of ipilimumab</masterLabel>
            <translation><!-- Practical use of ipilimumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Provide education/support for patient care improvement</masterLabel>
            <translation><!-- Provide education/support for patient care improvement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Provide guidance on the practical use of ipilimumab</masterLabel>
            <translation><!-- Provide guidance on the practical use of ipilimumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reactively discuss potential future indications for abatacept (including Sjogren’s, GCA, Myositis) outlining areas of unmet medical need and how abatacept’s unique mode of action may be relevant to these conditions</masterLabel>
            <translation><!-- Reactively discuss potential future indications for abatacept (including Sjogren’s, GCA, Myositis) outlining areas of unmet medical need and how abatacept’s unique mode of action may be relevant to these conditions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reinforce BMS commitment to Virology and leverage early HIV assets</masterLabel>
            <translation><!-- Reinforce BMS commitment to Virology and leverage early HIV assets --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Reinforce rationale for maintaining ATV in clin &amp; virol suppressed pts</masterLabel>
            <translation><!-- Reinforce rationale for maintaining ATV in clin &amp; virol suppressed pts --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Relative merits of measures of glycaemic control</masterLabel>
            <translation><!-- Relative merits of measures of glycaemic control --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to other unsolicited inquiries</masterLabel>
            <translation><!-- Respond to other unsolicited inquiries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to other unsolicited queries</masterLabel>
            <translation><!-- Respond to other unsolicited queries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to unsolicited inquiries</masterLabel>
            <translation><!-- Respond to unsolicited inquiries --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to unsolicited queries on the dasatinib compound</masterLabel>
            <translation><!-- Respond to unsolicited queries on the dasatinib compound --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Respond to unsolicited queries on the dasatinib compound including but not limited to Ph+ALL</masterLabel>
            <translation><!-- Respond to unsolicited queries on the dasatinib compound including but not limited to Ph+ALL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Review data from ALLY-2 showing the efficacy and safety of DCV combined with SOF in HIV/HCV co-infected patients</masterLabel>
            <translation><!-- Review data from ALLY-2 showing the efficacy and safety of DCV combined with SOF in HIV/HCV co-infected patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Review the replication cycle of HCV and the essential role of NS5A in HCV replication and assembly that makes it a key target  for DAA therapy</masterLabel>
            <translation><!-- Review the replication cycle of HCV and the essential role of NS5A in HCV replication and assembly that makes it a key target  for DAA therapy --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Review treatment challenges for peri-transplant patients</masterLabel>
            <translation><!-- Review treatment challenges for peri-transplant patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Role of ATV/r-based therapy in Women</masterLabel>
            <translation><!-- Role of ATV/r-based therapy in Women --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Role of ipilimumab in the treatment of metastatic melanoma</masterLabel>
            <translation><!-- Role of ipilimumab in the treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Role of ipilimumab in the treatment of pre-treated melanoma with a focus on the mode of action and the efficacy (Efficacy outcomes including the long term survival)</masterLabel>
            <translation><!-- Role of ipilimumab in the treatment of pre-treated melanoma with a focus on the mode of action and the efficacy (Efficacy outcomes including the long term survival) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safe and appropriate use of dasatinib</masterLabel>
            <translation><!-- Safe and appropriate use of dasatinib --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety and tolerability</masterLabel>
            <translation><!-- Safety and tolerability --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety of apixaban in post THR and TKR surgery</masterLabel>
            <translation><!-- Safety of apixaban in post THR and TKR surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Safety profile and appropriate use of dasatinib</masterLabel>
            <translation><!-- Safety profile and appropriate use of dasatinib --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Share Warfarin limitations of use demonstrated in Real World data and leverage the efficacy and safety benefits of NOACs and Apixaban versus Warfarin for NVAF patients</masterLabel>
            <translation><!-- Share Warfarin limitations of use demonstrated in Real World data and leverage the efficacy and safety benefits of NOACs and Apixaban versus Warfarin for NVAF patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Subcutaneous Abatacept Clinical Program: Communication of Phase 3 SC Clinical Data</masterLabel>
            <translation><!-- Subcutaneous Abatacept Clinical Program: Communication of Phase 3 SC Clinical Data --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Subgroups – Cancer</masterLabel>
            <translation><!-- Subgroups – Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Subgroups – Dose reduction / appropriate dosing</masterLabel>
            <translation><!-- Subgroups – Dose reduction / appropriate dosing --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Support VTEtx launch, differentiate apixaban from standard of care and contribute to value proposition discussions</masterLabel>
            <translation><!-- Support VTEtx launch, differentiate apixaban from standard of care and contribute to value proposition discussions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Support the differentiated apixaban profile</masterLabel>
            <translation><!-- Support the differentiated apixaban profile --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>The clinical efficacy and safety of dasatanib in CML providing practice informing information</masterLabel>
            <translation><!-- The clinical efficacy and safety of dasatanib in CML providing practice informing information --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Timing of administration after surgery</masterLabel>
            <translation><!-- Timing of administration after surgery --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Timing of administration perioperatively</masterLabel>
            <translation><!-- Timing of administration perioperatively --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Translate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA</masterLabel>
            <translation><!-- Translate the clinical relevance of abatacept’s unique MoA to positively alter the course of RA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treatment free remission (TFR) and cure are unmet needs for patients with CML</masterLabel>
            <translation><!-- Treatment free remission (TFR) and cure are unmet needs for patients with CML --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treatment of metastatic melanoma within guidelines and unmet medical need for patients</masterLabel>
            <translation><!-- Treatment of metastatic melanoma within guidelines and unmet medical need for patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Treatment of other genotypes with DCV+SOF</masterLabel>
            <translation><!-- Treatment of other genotypes with DCV+SOF --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet Medical Need in HCV</masterLabel>
            <translation><!-- Unmet Medical Need in HCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet medical need and guidelines on treatment of metastatic melanoma</masterLabel>
            <translation><!-- Unmet medical need and guidelines on treatment of metastatic melanoma --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unmet medical needs in type 2 diabetes</masterLabel>
            <translation><!-- Unmet medical needs in type 2 diabetes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Use of ATV in new treatment strategies, with and in light of new agents</masterLabel>
            <translation><!-- Use of ATV in new treatment strategies, with and in light of new agents --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Use of PI/r in naïve and early switch pts, with focus on long-term efficacy, tolerability, safety, and convenience of ATV/r</masterLabel>
            <translation><!-- Use of PI/r in naïve and early switch pts, with focus on long-term efficacy, tolerability, safety, and convenience of ATV/r --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Value to HCPs / patients / payers</masterLabel>
            <translation><!-- Value to HCPs / patients / payers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Warnings and cautions for use</masterLabel>
            <translation><!-- Warnings and cautions for use --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Weight loss</masterLabel>
            <translation><!-- Weight loss --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Medical Event --></label>
        <name>Medical_Event_vod__c</name>
        <relationshipLabel>Call Discussions</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Medical Plan Strategy --></label>
        <name>Medical_Plan_Strategy_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Mobile ID --></label>
        <name>Mobile_ID_vod__c</name>
    </fields>
    <fields>
        <label><!-- Next Call Objective --></label>
        <name>Next_Call_Objective_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>Awareness</masterLabel>
            <translation><!-- Awareness --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Increased Understanding</masterLabel>
            <translation><!-- Increased Understanding --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Integration / Extend</masterLabel>
            <translation><!-- Integration / Extend --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Positive Attitude / Try</masterLabel>
            <translation><!-- Positive Attitude / Try --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Overall Customer Feedback --></label>
        <name>Overall_Customer_Feedback_BMS_CA__c</name>
        <picklistValues>
            <masterLabel>Aware</masterLabel>
            <translation><!-- Aware --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disengagement</masterLabel>
            <translation><!-- Disengagement --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Initiating</masterLabel>
            <translation><!-- Initiating --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>On Board</masterLabel>
            <translation><!-- On Board --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Studying</masterLabel>
            <translation><!-- Studying --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Uninterested</masterLabel>
            <translation><!-- Uninterested --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Override Lock --></label>
        <name>Override_Lock_vod__c</name>
    </fields>
    <fields>
        <label><!-- Patient Type --></label>
        <name>Patient_Type_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>Advanced Ovarian Cancer</masterLabel>
            <translation><!-- Advanced Ovarian Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Core Message</masterLabel>
            <translation><!-- Core Message --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Defense Generic</masterLabel>
            <translation><!-- Defense Generic --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early-stage Breast Cancer</masterLabel>
            <translation><!-- Early-stage Breast Cancer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glucose uncontrol with mono Met dosage 1500mg above T2DM patients</masterLabel>
            <translation><!-- Glucose uncontrol with mono Met dosage 1500mg above T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HTN with CHD</masterLabel>
            <translation><!-- HTN with CHD --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HTN with MI (NSTEMI/STEMI)</masterLabel>
            <translation><!-- HTN with MI (NSTEMI/STEMI) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HTN with UA/A-PCI</masterLabel>
            <translation><!-- HTN with UA/A-PCI --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Heart Failure</masterLabel>
            <translation><!-- Heart Failure --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>New T2DM patients</masterLabel>
            <translation><!-- New T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>New diagnosed T2DM patients</masterLabel>
            <translation><!-- New diagnosed T2DM patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OC</masterLabel>
            <translation><!-- OC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SCLC</masterLabel>
            <translation><!-- SCLC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TKR patients</masterLabel>
            <translation><!-- TKR patients --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Pipeline / Other --></label>
        <name>Pipeline_Other_BMS_CA__c</name>
        <picklistValues>
            <masterLabel>11βHSD Inhibitors</masterLabel>
            <translation><!-- 11βHSD Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ABILIFY® (aripiprazole)</masterLabel>
            <translation><!-- ABILIFY® (aripiprazole) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate)</masterLabel>
            <translation><!-- ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVALIDE® (irbesartan hydrochlorothiazide)</masterLabel>
            <translation><!-- AVALIDE® (irbesartan hydrochlorothiazide) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>AVAPRO® (irbesartan)</masterLabel>
            <translation><!-- AVAPRO® (irbesartan) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD28</masterLabel>
            <translation><!-- Anti-CD28 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD40L</masterLabel>
            <translation><!-- Anti-CD40L --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CD70 ADC</masterLabel>
            <translation><!-- Anti-CD70 ADC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-CXCR4</masterLabel>
            <translation><!-- Anti-CXCR4 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IL31</masterLabel>
            <translation><!-- Anti-IL31 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IL6</masterLabel>
            <translation><!-- Anti-IL6 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-IP10</masterLabel>
            <translation><!-- Anti-IP10 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-KIR</masterLabel>
            <translation><!-- Anti-KIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-LAG3</masterLabel>
            <translation><!-- Anti-LAG3 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-PD-L1</masterLabel>
            <translation><!-- Anti-PD-L1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Anti-PD1</masterLabel>
            <translation><!-- Anti-PD1 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Asunaprevir (NS3 Inhibitor)</masterLabel>
            <translation><!-- Asunaprevir (NS3 Inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Avagacestat (Gamma Secretase Inhibitor)</masterLabel>
            <translation><!-- Avagacestat (Gamma Secretase Inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Aβ Modulator</masterLabel>
            <translation><!-- Aβ Modulator --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE® (entecavir)</masterLabel>
            <translation><!-- BARACLUDE® (entecavir) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BICNU® (carmustine)</masterLabel>
            <translation><!-- BICNU® (carmustine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BUSPAR® (buspirone hydrochloride)</masterLabel>
            <translation><!-- BUSPAR® (buspirone hydrochloride) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Brivanib</masterLabel>
            <translation><!-- Brivanib --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CCR1 Antagonists</masterLabel>
            <translation><!-- CCR1 Antagonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CCR2 / 5</masterLabel>
            <translation><!-- CCR2 / 5 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CEENU® (lomustine)</masterLabel>
            <translation><!-- CEENU® (lomustine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CGRP Antagonist</masterLabel>
            <translation><!-- CGRP Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>COUMADIN® (warfarin sodium)</masterLabel>
            <translation><!-- COUMADIN® (warfarin sodium) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CVMet General</masterLabel>
            <translation><!-- CVMet General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DROXIA® (hydroxyurea)</masterLabel>
            <translation><!-- DROXIA® (hydroxyurea) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Daclatasvir (NS5A inhibitor)</masterLabel>
            <translation><!-- Daclatasvir (NS5A inhibitor) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EGFR/IGFR Tandem Adnectin</masterLabel>
            <translation><!-- EGFR/IGFR Tandem Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ERBITUX® (cetuximab)</masterLabel>
            <translation><!-- ERBITUX® (cetuximab) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ETOPOPHOS® (etoposide phosphate)</masterLabel>
            <translation><!-- ETOPOPHOS® (etoposide phosphate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Eliquis® (apixaban)</masterLabel>
            <translation><!-- Eliquis® (apixaban) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Elotuzumab</masterLabel>
            <translation><!-- Elotuzumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FGF21-PKE Adnectin</masterLabel>
            <translation><!-- FGF21-PKE Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>FORXIGA® (dapagliflozin)</masterLabel>
            <translation><!-- FORXIGA® (dapagliflozin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GABA/Nicotinic Modulator</masterLabel>
            <translation><!-- GABA/Nicotinic Modulator --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GLUCOPHAGE® (metformin hydrochloride)</masterLabel>
            <translation><!-- GLUCOPHAGE® (metformin hydrochloride) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GPR119 Agonists</masterLabel>
            <translation><!-- GPR119 Agonists --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Attachment Inhibitor</masterLabel>
            <translation><!-- HIV Attachment Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV General</masterLabel>
            <translation><!-- HIV General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV Maturation Inhibitor</masterLabel>
            <translation><!-- HIV Maturation Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HYDREA® (hydroxyurea)</masterLabel>
            <translation><!-- HYDREA® (hydroxyurea) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Hepatitis General</masterLabel>
            <translation><!-- Hepatitis General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IGF-1R Antagonist</masterLabel>
            <translation><!-- IGF-1R Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IKACh Inhibitors</masterLabel>
            <translation><!-- IKACh Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IKur</masterLabel>
            <translation><!-- IKur --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IL-21</masterLabel>
            <translation><!-- IL-21 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IL-23 Adnectin</masterLabel>
            <translation><!-- IL-23 Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMS General</masterLabel>
            <translation><!-- IMS General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IXEMPRA® (ixabepilone)</masterLabel>
            <translation><!-- IXEMPRA® (ixabepilone) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>JAK2 Inhibitor</masterLabel>
            <translation><!-- JAK2 Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release)</masterLabel>
            <translation><!-- KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LPA1 Antagonist</masterLabel>
            <translation><!-- LPA1 Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LXR Modulators</masterLabel>
            <translation><!-- LXR Modulators --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Mature Brands General</masterLabel>
            <translation><!-- Mature Brands General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Microtubule Stabilizer</masterLabel>
            <translation><!-- Microtubule Stabilizer --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NRT Inhibitor</masterLabel>
            <translation><!-- NRT Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS General</masterLabel>
            <translation><!-- NS General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5A Second Generation</masterLabel>
            <translation><!-- NS5A Second Generation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Inhibitor</masterLabel>
            <translation><!-- NS5B Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Primer Grip Inhibitor</masterLabel>
            <translation><!-- NS5B Primer Grip Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NS5B Site 1 Inhibitor</masterLabel>
            <translation><!-- NS5B Site 1 Inhibitor --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NULOJIX® (belatacept)</masterLabel>
            <translation><!-- NULOJIX® (belatacept) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Necitumumab</masterLabel>
            <translation><!-- Necitumumab --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Notch Inhibitors</masterLabel>
            <translation><!-- Notch Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA® (saxagliptin)</masterLabel>
            <translation><!-- ONGLYZA® (saxagliptin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA® (abatacept)</masterLabel>
            <translation><!-- ORENCIA® (abatacept) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Oncology General</masterLabel>
            <translation><!-- Oncology General --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PCSK9 Adnectin</masterLabel>
            <translation><!-- PCSK9 Adnectin --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PEG-FGF21</masterLabel>
            <translation><!-- PEG-FGF21 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PLAVIX® (clopidogrel bisulfate)</masterLabel>
            <translation><!-- PLAVIX® (clopidogrel bisulfate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PRAVACHOL® (pravastatin sodium)</masterLabel>
            <translation><!-- PRAVACHOL® (pravastatin sodium) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Pegdinetanib (VEGF R-2 Adnectin)</masterLabel>
            <translation><!-- Pegdinetanib (VEGF R-2 Adnectin) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Peginterferon lambda-1a</masterLabel>
            <translation><!-- Peginterferon lambda-1a --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RECOTHROM® Thrombin, topical (recombinant)</masterLabel>
            <translation><!-- RECOTHROM® Thrombin, topical (recombinant) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYATAZ® (atazanavir sulfate)</masterLabel>
            <translation><!-- REYATAZ® (atazanavir sulfate) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SMO Antagonist</masterLabel>
            <translation><!-- SMO Antagonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL® (dasatinib)</masterLabel>
            <translation><!-- SPRYCEL® (dasatinib) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SUSTIVA® (efavirenz)</masterLabel>
            <translation><!-- SUSTIVA® (efavirenz) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TAXOL® (paclitaxel)</masterLabel>
            <translation><!-- TAXOL® (paclitaxel) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TGR5 agonist</masterLabel>
            <translation><!-- TGR5 agonist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tempra IV® (paracetamol)</masterLabel>
            <translation><!-- Tempra IV® (paracetamol) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Triple Reuptake Inhibitors</masterLabel>
            <translation><!-- Triple Reuptake Inhibitors --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Urelumab (Anti-CD137)</masterLabel>
            <translation><!-- Urelumab (Anti-CD137) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VIDEX® (didanosine)</masterLabel>
            <translation><!-- VIDEX® (didanosine) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY™ (ipilimumab)</masterLabel>
            <translation><!-- YERVOY™ (ipilimumab) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>α-7 Nicotinic Agonist</masterLabel>
            <translation><!-- α-7 Nicotinic Agonist --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Presentation --></label>
        <name>Presentation__c</name>
        <picklistValues>
            <masterLabel>CHS Diabetic Presentation</masterLabel>
            <translation><!-- CHS Diabetic Presentation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CHS Presentation</masterLabel>
            <translation><!-- CHS Presentation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CR Presentation</masterLabel>
            <translation><!-- CR Presentation --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CR Presentation Diabetic Patients</masterLabel>
            <translation><!-- CR Presentation Diabetic Patients --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RLS Presentation</masterLabel>
            <translation><!-- RLS Presentation --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Product Knowledge --></label>
        <name>Product_Knowledge_BMS_CN__c</name>
        <picklistValues>
            <masterLabel>1 - Significant Gaps of Product Profile</masterLabel>
            <translation><!-- 1 - Significant Gaps of Product Profile --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>2 - Unable to comm general Med attributes</masterLabel>
            <translation><!-- 2 - Unable to comm general Med attributes --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>3 - Significant gaps in TA Knowledge</masterLabel>
            <translation><!-- 3 - Significant gaps in TA Knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>4 - Variable knowledge of TA on diff topics</masterLabel>
            <translation><!-- 4 - Variable knowledge of TA on diff topics --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>5 - Some misunderstandings of Product</masterLabel>
            <translation><!-- 5 - Some misunderstandings of Product --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>6 - Minor Gaps in BMS Product Knowledge</masterLabel>
            <translation><!-- 6 - Minor Gaps in BMS Product Knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>7 - High level of general TA Knowledge</masterLabel>
            <translation><!-- 7 - High level of general TA Knowledge --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>8 - Ability to accurately comm Product</masterLabel>
            <translation><!-- 8 - Ability to accurately comm Product --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>9 - Detailed Product knowledge</masterLabel>
            <translation><!-- 9 - Detailed Product knowledge --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label>Compound Related Deck</label>
        <name>Product_Presentation_Proactive_Deck_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- Product Strategy --></label>
        <name>Product_Strategy_vod__c</name>
        <relationshipLabel>Call Discussions</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Product Tactic --></label>
        <name>Product_Tactic_vod__c</name>
        <relationshipLabel>Call Discussions</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Product --></label>
        <name>Product_vod__c</name>
        <relationshipLabel>Call Discussions</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Proposed Segment --></label>
        <name>Proposed_Segment_BMS_EMEA__c</name>
        <picklistValues>
            <masterLabel>BARACLUDE Proposed Segment A</masterLabel>
            <translation><!-- BARACLUDE Proposed Segment A --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Believers</masterLabel>
            <translation><!-- Believers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Cautious Experimenters</masterLabel>
            <translation><!-- Cautious Experimenters --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Consider all PD1 the same</masterLabel>
            <translation><!-- Consider all PD1 the same --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Disengaged Traditionalist</masterLabel>
            <translation><!-- Disengaged Traditionalist --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Early Line User</masterLabel>
            <translation><!-- Early Line User --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Fast, broad adoption of DAAs</masterLabel>
            <translation>Segm A-Broad use</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Glivec First</masterLabel>
            <translation><!-- Glivec First --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Growing Use in 1st bio switch</masterLabel>
            <translation><!-- Growing Use in 1st bio switch --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Holistic Sprycel users</masterLabel>
            <translation><!-- Holistic Sprycel users --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Late line user</masterLabel>
            <translation><!-- Late line user --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Low or No IV Capacity</masterLabel>
            <translation><!-- Low or No IV Capacity --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Lower, conservative use of DAAs</masterLabel>
            <translation>Segm C-Interested in GT3</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>More cautious adoption of DAAs</masterLabel>
            <translation>Segm B-Commit on GT3</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>No interest/No use</masterLabel>
            <translation>No Segm-No interest/No use</translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers BRAF/MEK Inhibitors 1st line</masterLabel>
            <translation><!-- Prefers BRAF/MEK Inhibitors 1st line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers Keytruda</masterLabel>
            <translation><!-- Prefers Keytruda --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers Opdivo</masterLabel>
            <translation><!-- Prefers Opdivo --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Prefers Yervoy 1st line</masterLabel>
            <translation><!-- Prefers Yervoy 1st line --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Simple Decisions</masterLabel>
            <translation><!-- Simple Decisions --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Tasigna Belivers</masterLabel>
            <translation><!-- Tasigna Belivers --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Unconvienced Followers</masterLabel>
            <translation><!-- Unconvienced Followers --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Question --></label>
        <name>Question_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Restricted Comments --></label>
        <name>Restricted_Comments__c</name>
    </fields>
    <fields>
        <label><!-- Slides --></label>
        <name>Slides__c</name>
    </fields>
    <fields>
        <label><!-- Source --></label>
        <name>Source_BMS__c</name>
    </fields>
    <fields>
        <label>Congress Material</label>
        <name>Speaker_Training_Proactive_Deck_BMS__c</name>
        <relationshipLabel><!-- Interaction Discussions --></relationshipLabel>
    </fields>
    <fields>
        <label><!-- User --></label>
        <name>User_vod__c</name>
        <relationshipLabel>Call Discussions</relationshipLabel>
    </fields>
    <fields>
        <label><!-- Webcast ID --></label>
        <name>Webcast_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- Y --></label>
        <name>Y_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Deck Name --></label>
        <name>iPlan_Deck_Name_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Product ID --></label>
        <name>iPlan_Product_ID_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Product Name --></label>
        <name>iPlan_Product_Name_BMS__c</name>
    </fields>
    <fields>
        <label><!-- iPlan Status --></label>
        <name>iPlan_Status_BMS__c</name>
        <picklistValues>
            <masterLabel>Invalid CMEH ID</masterLabel>
            <translation><!-- Invalid CMEH ID --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Invalid Slide Deck ID</masterLabel>
            <translation><!-- Invalid Slide Deck ID --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>Success</masterLabel>
            <translation><!-- Success --></translation>
        </picklistValues>
    </fields>
    <fields>
        <label><!-- Product --></label>
        <name>zvod_Product_Map_vod__c</name>
        <picklistValues>
            <masterLabel>ABATACEPT</masterLabel>
            <translation><!-- ABATACEPT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>APIXABAN</masterLabel>
            <translation><!-- APIXABAN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATAZANAVIR</masterLabel>
            <translation><!-- ATAZANAVIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ATRIAL FIBRILLATION (APIXABAN)</masterLabel>
            <translation><!-- ATRIAL FIBRILLATION (APIXABAN) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BARACLUDE</masterLabel>
            <translation><!-- BARACLUDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BELATACEPT</masterLabel>
            <translation><!-- BELATACEPT --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BIOMARKERS (ONCOLOGY)</masterLabel>
            <translation><!-- BIOMARKERS (ONCOLOGY) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BLADDER (NIVOLUMAB)</masterLabel>
            <translation><!-- BLADDER (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-663068-03</masterLabel>
            <translation><!-- BMS-663068-03 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-931699-01</masterLabel>
            <translation><!-- BMS-931699-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986001</masterLabel>
            <translation><!-- BMS-986001 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986001-01</masterLabel>
            <translation><!-- BMS-986001-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986004-01</masterLabel>
            <translation><!-- BMS-986004-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986090-01</masterLabel>
            <translation><!-- BMS-986090-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986104-01</masterLabel>
            <translation><!-- BMS-986104-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986142-01</masterLabel>
            <translation><!-- BMS-986142-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986165-01</masterLabel>
            <translation><!-- BMS-986165-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986166-02</masterLabel>
            <translation><!-- BMS-986166-02 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986184-01</masterLabel>
            <translation><!-- BMS-986184-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986195-01</masterLabel>
            <translation><!-- BMS-986195-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BMS-986202-01</masterLabel>
            <translation><!-- BMS-986202-01 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BRIVANIB</masterLabel>
            <translation><!-- BRIVANIB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYDUREON</masterLabel>
            <translation><!-- BYDUREON --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>BYETTA</masterLabel>
            <translation><!-- BYETTA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CARDIOVASCULAR</masterLabel>
            <translation><!-- CARDIOVASCULAR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>CHRONIC MYLOID LEUKEMIA/ACUTE LYMPHOCYTIC LEUKEMIA (DASATINIB)</masterLabel>
            <translation><!-- CHRONIC MYLOID LEUKEMIA/ACUTE LYMPHOCYTIC LEUKEMIA (DASATINIB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>COLORECTAL (NIVOLUMAB)</masterLabel>
            <translation><!-- COLORECTAL (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DACLATASVIR DIHYDROCHLORIDE</masterLabel>
            <translation><!-- DACLATASVIR DIHYDROCHLORIDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAKLINZA</masterLabel>
            <translation><!-- DAKLINZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DAPAGLIFLOZIN</masterLabel>
            <translation><!-- DAPAGLIFLOZIN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DASATINIB</masterLabel>
            <translation><!-- DASATINIB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>DELETE</masterLabel>
            <translation><!-- DELETE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EFAVIRENZ</masterLabel>
            <translation><!-- EFAVIRENZ --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ELIQUIS</masterLabel>
            <translation><!-- ELIQUIS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ELOTUZUMAB</masterLabel>
            <translation><!-- ELOTUZUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EMPLICITI</masterLabel>
            <translation><!-- EMPLICITI --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ENTECAVIR</masterLabel>
            <translation><!-- ENTECAVIR --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>EXENATIDE</masterLabel>
            <translation><!-- EXENATIDE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GASTRIC (NIVOLUMAB)</masterLabel>
            <translation><!-- GASTRIC (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>GLIOBLASTOMA (NIVOLUMAB)</masterLabel>
            <translation><!-- GLIOBLASTOMA (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HBV</masterLabel>
            <translation><!-- HBV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCC (NIVOLUMAB)</masterLabel>
            <translation><!-- HCC (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV</masterLabel>
            <translation><!-- HCV --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HCV Portfolio</masterLabel>
            <translation><!-- HCV Portfolio --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEAD AND NECK (NIVOLUMAB)</masterLabel>
            <translation><!-- HEAD AND NECK (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEMATOLOGY</masterLabel>
            <translation><!-- HEMATOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HEPATITIS (ENTECAVIR/HCV PORTFOLIO)</masterLabel>
            <translation><!-- HEPATITIS (ENTECAVIR/HCV PORTFOLIO) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV (ATAZANAVIR/EFAVIRENZ)</masterLabel>
            <translation><!-- HIV (ATAZANAVIR/EFAVIRENZ) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV NRTI BMS-986001</masterLabel>
            <translation><!-- HIV NRTI BMS-986001 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>HIV attachment inhibitor BMS-663068</masterLabel>
            <translation><!-- HIV attachment inhibitor BMS-663068 --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMMUNO-ONCOLOGY</masterLabel>
            <translation><!-- IMMUNO-ONCOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IMMUNOLOGY</masterLabel>
            <translation><!-- IMMUNOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>IPILIMUMAB</masterLabel>
            <translation><!-- IPILIMUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>KOMBOGLYZE</masterLabel>
            <translation><!-- KOMBOGLYZE --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LUNG (IPILIMUMAB/NIVOLUMAB)</masterLabel>
            <translation><!-- LUNG (IPILIMUMAB/NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LUNG (NIVOLUMAB)</masterLabel>
            <translation><!-- LUNG (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>LYMPHOMA (NIVOLUMAB)</masterLabel>
            <translation><!-- LYMPHOMA (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA</masterLabel>
            <translation><!-- MELANOMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA (IPILIMUMAB)</masterLabel>
            <translation><!-- MELANOMA (IPILIMUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA (IPILIMUMAB/NIVOLUMAB)</masterLabel>
            <translation><!-- MELANOMA (IPILIMUMAB/NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MELANOMA (NIVOLUMAB)</masterLabel>
            <translation><!-- MELANOMA (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>MULTIPLE MYELOMA (ELOTUZUMAB)</masterLabel>
            <translation><!-- MULTIPLE MYELOMA (ELOTUZUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NIVOLUMAB</masterLabel>
            <translation><!-- NIVOLUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NIVOLUMAB BMS</masterLabel>
            <translation><!-- NIVOLUMAB BMS --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NIVOLUMAB BMS LUNG</masterLabel>
            <translation><!-- NIVOLUMAB BMS LUNG --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>NON-BRANDED ACTIVITY</masterLabel>
            <translation><!-- NON-BRANDED ACTIVITY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OESOPHAGEAL (NIVOLUMAB)</masterLabel>
            <translation><!-- OESOPHAGEAL (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONCOLOGY</masterLabel>
            <translation><!-- ONCOLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ONGLYZA</masterLabel>
            <translation><!-- ONGLYZA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO</masterLabel>
            <translation><!-- OPDIVO --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO LUNG</masterLabel>
            <translation><!-- OPDIVO LUNG --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO MELANOMA</masterLabel>
            <translation><!-- OPDIVO MELANOMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>OPDIVO RCC</masterLabel>
            <translation><!-- OPDIVO RCC --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ORENCIA</masterLabel>
            <translation><!-- ORENCIA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PANCREATIC (NIVOLUMAB)</masterLabel>
            <translation><!-- PANCREATIC (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>PROSTATE (NIVOLUMAB)</masterLabel>
            <translation><!-- PROSTATE (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REGIMEN (OPDIVO + YERVOY) MELANOMA</masterLabel>
            <translation><!-- REGIMEN (OPDIVO + YERVOY) MELANOMA --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RENAL (NIVOLUMAB)</masterLabel>
            <translation><!-- RENAL (NIVOLUMAB) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>REYATAZ</masterLabel>
            <translation><!-- REYATAZ --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>RHEUMATOID ARTHRITIS (ABATACEPT)</masterLabel>
            <translation><!-- RHEUMATOID ARTHRITIS (ABATACEPT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SAXAGLITPTIN</masterLabel>
            <translation><!-- SAXAGLITPTIN --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>SPRYCEL</masterLabel>
            <translation><!-- SPRYCEL --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>TRANSPLANT (BELATACEPT)</masterLabel>
            <translation><!-- TRANSPLANT (BELATACEPT) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>ULOCUPLUMAB</masterLabel>
            <translation><!-- ULOCUPLUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>URELUMAB</masterLabel>
            <translation><!-- URELUMAB --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VENOUS THROMBOEMBOLISM (APIXABAN)</masterLabel>
            <translation><!-- VENOUS THROMBOEMBOLISM (APIXABAN) --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>VIROLOGY</masterLabel>
            <translation><!-- VIROLOGY --></translation>
        </picklistValues>
        <picklistValues>
            <masterLabel>YERVOY</masterLabel>
            <translation><!-- YERVOY --></translation>
        </picklistValues>
    </fields>
    <recordTypes>
        <label><!-- BMS - CAN - KAM Interaction --></label>
        <name>BMS_CAN_KAM_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CAN - MSL Interaction --></label>
        <name>BMS_CAN_MSL_Interaction_BMS_CANADA</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CAN - Sales Rep Interaction --></label>
        <name>BMS_CAN_Sales_Rep_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA MSL Interaction --></label>
        <name>BMS_CHINA_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA SALES Interaction --></label>
        <name>BMS_CHINA_SALES_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (1Group Call) --></label>
        <name>BMS_CHINA_Sales_Interaction_Group_Call</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (Others) --></label>
        <name>BMS_CHINA_Sales_Interaction_Others</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (2Reminder Call) --></label>
        <name>BMS_CHINA_Sales_Interaction_Reminder_Call</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - CHINA Sales Interaction (3Social Call) --></label>
        <name>BMS_CHINA_Sales_Interaction_Social_Call</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - EMEA - EPM Interaction --></label>
        <name>BMS_EMEA_EPM_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - EMEA - HQ Interaction --></label>
        <name>BMS_EMEA_HQ_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - EMEA MSL Interaction --></label>
        <name>BMS_EMEA_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - EMEA Sales Rep Interaction --></label>
        <name>BMS_EMEA_Sales_Rep_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - MEA MSL Interaction --></label>
        <name>BMS_MEA_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - MEA Sales Rep Interaction --></label>
        <name>BMS_MEA_Sales_Rep_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - MSL Interaction --></label>
        <name>BMS_MSL_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label><!-- BMS - Non-Branded Interaction --></label>
        <name>BMS_Non_Branded_Interaction</name>
    </recordTypes>
    <recordTypes>
        <label>Call Report</label>
        <name>CallReport_vod</name>
    </recordTypes>
    <recordTypes>
        <label><!-- Event_vod --></label>
        <name>Event_vod</name>
    </recordTypes>
    <recordTypes>
        <label>MSL Meeting Brief</label>
        <name>MSLMeetingBrief_vod</name>
    </recordTypes>
    <recordTypes>
        <label>Meeting Brief</label>
        <name>MeetingBrief_vod</name>
    </recordTypes>
    <startsWith>Consonant</startsWith>
    <validationRules>
        <errorMessage><!-- A Clinical Trial must be selected when Topic is CT and must be left empty otherwise. --></errorMessage>
        <name>BMS_EMEA_CTrequiredForMSMScenarios</name>
    </validationRules>
    <validationRules>
        <errorMessage><!-- Engagement Activity : Account should be the same the Interaction: Account --></errorMessage>
        <name>BMS_EMEA_EA_Account_Match_On_Interaction</name>
    </validationRules>
    <validationRules>
        <errorMessage><!-- A Medical Communication Topic must be selected when Topic is MCT and must be left empty otherwise. --></errorMessage>
        <name>BMS_EMEA_MCTrequiredForMSMScenarios</name>
    </validationRules>
</CustomObjectTranslation>
